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ABSTRACT 
     
     Linda Vanessa Kalilani 
Malaria in Pregnancy and Drug Therapies in Malawi 
(Under the direction of Prof Steven R. Meshnick) 
 
In this dissertation, I  investigated the effect of timing and frequency of  
Plasmodium falciparum infection during pregnancy on the risk of low birth weight and  
maternal anemia. I also investigated the efficacy of sulfadoxine-pyrimethamine combined  
with azithromycin or artesunate compared with sulfadoxine-pyrimethamine monotherapy  
as treatment for uncomplicated Plasmodium falciparum infection in pregnant women.  
 
We conducted a prospective observational study recruiting 2,462 pregnant women 
in Malawi. Malaria was assessed during follow-up and delivery. Birth weight and 
hemoglobin concentration were measured at delivery. The prevalence of low birth weight 
increased with the number of malaria episodes: [1 episode (prevalence ratio [PR] =2.17; 
95% C.I. 1.22-3.86), and 2 episodes (PR=3.68; 95% C.I. 1.81-7.47)]. The prevalence of 
anemia increased with the number of episodes of malaria: [1 episode (PR= 1.16; 95% C.I. 
0.77-1.77) and 2 episodes (PR= 1.82 95% C.I. 1.04-3.19)]. The prevalence of low birth 
weight was higher with infection in the second trimester (PR=2.97; 95% CI 1.60-5.53) 
than in the third trimester (PR=1.42; 95% CI 0.63-3.22). The prevalence of maternal 
anemia was higher with infection in the third trimester (PR=1.44; 95% CI 0.90-2.29) than 
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in the second trimester (PR=0.94; 95% CI 0.51-1.71). Timing and frequency of infection 
affect the risk of maternal anemia and low birth weight.  
 
We conducted a randomized open-label clinical trial, recruiting 141 pregnant 
women. They were randomly allocated to 3 treatment groups: sulfadoxine-pyrimethamine 
(SP; 3 tablets, 500mg sulfadoxine and 25mg pyrimethamine per tablet); SP plus 
azithromycin (1g/day x 2 days); or SP plus artesunate (400mg/day x 3 days). All treatment 
regimens were well tolerated. Two women vomited soon after ingesting azithromycin. 
Recrudescent episodes of malaria were less frequent with SP-azithromycin [Hazard Ratio 
0.14 (95% confidence interval 0.02 to 0.78)] and SP-artesunate [Hazard Ratio 0.13 (95% 
confidence interval 0.03 to 0.53)] compared with SP monotherapy. There were more 
abortions in the SP-azithromycin group, and more stillbirths in the SP-artesunate groups, 
but they were probably unrelated to treatment. A larger study is needed to determine its 
safety and efficacy in preventing poor birth outcomes.  
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CHAPTER 1 
 
BACKGROUND AND SIGNIFICANCE 
1.1. Introduction 
Each year, approximately 50 million women become pregnant in malaria-endemic 
areas 1. Malaria infection during pregnancy can result in adverse pregnancy outcomes. It is 
estimated that each year malaria infection during pregnancy is responsible for 5 to 12% of 
all low birth weight (LBW) deliveries, 30% of preventable LBW deliveries, and 3 to 8% 
of infant deaths globally 2. Malaria in pregnant women is also responsible for as many as 
400,000 cases of severe anemia annually in sub-Saharan Africa 3.  
 
Although the adverse effects of malaria infection during pregnancy are well 
known, there is limited information on the effect of timing and frequency of malaria 
infection during pregnancy on the risk of low birth weight and maternal anemia.  A few 
studies that have assessed the effect of timing of infection on LBW and maternal anemia 
have used placental pathology at delivery to define timing of infection which could have 
resulted in misclassification 4-7. One of the strategies recommended by the World Health 
Organization (WHO) for prevention of malaria and its adverse effects in pregnant women 
in malaria-endemic areas in sub-Saharan Africa is intermittent preventive therapy (IPT) 8. 
Information on the effect of frequency and timing of infection on these adverse outcomes 
would be important for developing effective policies in the prevention of malaria in 
pregnant women. It would help identify the time when IPT would be most effective in 
preventing LBW and maternal anemia. This is especially important in malaria endemic 
areas where most women do not have access to antenatal services and anti-malarial drugs 
are usually in short supply due to lack of resources.  
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Sulfadoxine-pyrimethamine (SP) is currently the drug of choice for IPT in many 
countries in sub-Saharan African countries and has been shown to reduce the prevalence 
of parasitemia and anemia in pregnant women, and increase birth weight 9-11. Resistance 
to SP is increasing rapidly in these areas 12. There are at present very few alternative drugs 
available for use for IPT during pregnancy, because of lack of data on the safety in the 
fetus. As drug resistance to SP spreads and intensifies, there is an urgent need to identify 
other drug alternatives for treatment and prevention of malaria in pregnancy.   
 
In this dissertation, I will use data from a prospective study that was conducted in 
Malawi to investigate the effect of timing and frequency of Plasmodium falciparum 
infection during pregnancy on the risk for LBW and maternal anemia (specific aim I). To 
identify new treatment alternatives for SP, I will use data from a clinical trial that was also 
conducted in Malawi to assess the efficacy and safety of SP combined with azithromycin 
or artesunate in treating and preventing malaria in pregnant women (specific aim II).    
 
1.2. Malaria in Malawi 
Malawi is located in South-East Africa, covering an area of 45,745 square miles  
(118,484km2), with a population of 12 million 13.Women in the reproductive age (15-49  
years), and children less than 5 years comprise 24% and 17% of the population  
respectively 13. Malawi has a tropical continental climate with a dry season from August  
to October, and a rainy season from November to March. Malaria transmission occurs all  
year round, but peaks during the rainy (November–March). P. falciparum causes over  
90% of all malaria infections. Malaria continues to be the leading cause of morbidity and  
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mortality particularly among children under the age of five years and pregnant women. It  
is estimated that there have been more than 8 million cases of malaria per year in Malawi,  
over the past 5 years 14. Most of these cases were in children less than 5 years of age, who  
experience on average 9.7 malaria episodes each year 15, 16. Forty percent of all hospital 
 admissions, and 30% of all hospital deaths in children less than 5 years of  age are due to  
malaria and its associated complications such as anemia. Although most infections in  
pregnant women are asymptomatic, parasitemia has been detected in up to 40% of   
pregnant women presenting for antenatal care 11, 17. Malaria also causes 20% of the  
anemia cases in pregnant women 11.  
 
Malaria also imposes substantial costs, both directly and indirectly due to potential 
loss of income from days of work lost and hospital and drug expenses. It is estimated that 
the total cost of malaria to the average Malawian household is US$35, or 7.2% of the 
average annual household income 18. For very low-income households (40% of all 
Malawian households), the annual cost of malaria is nearly US$20, or 32% of annual 
household income. 
 
Chloroquine (CQ) was used as the first line treatment for malaria, and  
chemoprophylaxis in pregnant women.  Due to high levels of resistance, Malawi became 
the fist country in Africa to replace CQ with SP in 1993 as the first-line drug for treatment 
of uncomplicated P. falciparum malaria. It was also the first country to recommend that 
all pregnant women should receive at least two doses of SP IPT during pregnancy in the 
second trimester and early in the third trimester, which was shown to decrease the 
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prevalence of peripheral and placental parasitemia, maternal anemia and LBW 11, 19. 
Malaria has been identified by women in Malawi as one of the most commonly identified 
maternal health problems in the ante-partum period, and the awareness for the need for SP 
during pregnancy is high 20,21. However, only 79% of the pregnant women receive one 
dose of SP, and less than half (43%) receive the recommended two-dose regimen due to 
limited access to antenatal care services and lack of drugs in health facilities 14,21. 
 
The level of SP resistance in Malawi has been steadily increasing since its 
introduction in 1993. A study conducted in the northern part of Malawi between 1995 and 
1996 reported a high prevalence of mutations associated with SP resistance 22. Another 
study conducted in the central region of Malawi in 1997, found that 78% of the samples 
had quintuple mutations, which are highly associated with resistance to SP 23. In vivo and 
in vitro studies conducted in all three regions of Malawi from 1994 and 1998 reported 
clinical efficacy to SP in children less than 5 years of age ranging from 81% to 88% 24-26. 
This indicates that SP resistance is high in Malawi and there is an urgent need to conduct 
research to identify new alternative anti-malarial therapies to replace SP for the future. 
 
1.3. Malaria 
Malaria is a vector-borne parasitic disease caused by protozoa belonging to the 
genus Plasmodium. Four species are known to infect human beings: P. falciparum, P. 
ovale, P. vivax and P. malariae. The majority of infections are caused by the two species, 
P. falciparum and P. vivax. P. falciparum is responsible for most severe disease 27. The 
distribution of these Plasmodium species is dependent on ecological (temperature, 
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humidity, presence of breeding sites) and behavioral parameters affecting the ability of 
mosquitoes to transmit Plasmodium species 28. P. falciparum malaria is widespread in the 
tropic regions in sub-Saharan Africa, certain areas of South-East Asia, Oceania and the 
Amazon Basin of South America 27 (Figure 1.1). P. vivax malaria has a wider geographic 
distribution compared to P. falciparum 29. It is commonly found in most of Asia, parts of 
the Americas, eastern Europe and North Africa. P. ovale is found primarily in tropical 
western Africa and P. malariae is found only in pockets, particularly in Africa 30.  
 
1.4. Transmission and life cycle of Plasmodium species 
Malaria is transmitted to humans by over 40 species of female Anopheline 
mosquitoes (Figure 1.2). The infective parasites, in an active form called sporozoites, are 
released from salivary glands and injected into the human blood through a bite by an 
infected female Anopheles mosquito. The sporozoites rapidly invade liver cells within 30 
to 45 minutes, beginning the pre-erythrocytic stage of the life cycle. In the liver cells, the 
sporozoites undergo asexual replication and develop into merozoites which are capable of 
invading red blood cells (erythrocytes). At the end of the pre-erythrocytic stage, parasites 
in the liver induce death and detachment of the liver cells, and budding of parasite-filled 
vesicles (merosomes) 31. The merosomes migrate from the liver into the bloodstream, 
where they rupture, and thousands of merozoites are released into the blood stream. The 
merozoites attach to, and invade erythrocytes, beginning the erythrocytic cycle. The 
period it takes for parasites to multiply in the liver is species dependent, varying from 6 to 
7 days for P. falciparum to 14 to 16 days for P. malariae.  The P. vivax and P. ovale 
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parasites may remain dormant in the liver for months to years as hypnozoites before 
infecting red blood cells, and causing a relapse after the initial event 32.  
 
In the erythrocytic stage, merozoites multiply asexually in erythrocytes, and 
depending on the species, produce 8 to 32 progeny merozoites. The merozoites are 
released from the erythrocytes with the destruction of the erythrocyte, and immediately 
invade other erythrocytes. This asexual erythrocytic cycle continues until it is controlled 
by the host’s immune response, therapy or until the host dies. A small percentage of the 
merozoites undergo sexual replication and differentiate into male and female gametocytes. 
P. vivax gametocytes develop soon after the release of merozoites from the liver, whereas 
P. falciparum gametocytes develop much later 33. These gametocytes are eventually taken 
up by a female Anopheles mosquito during a blood feed. The gametocytes develop and 
mature, undergoing sexual reproduction in the stomach wall of the mosquito, producing 
approximately 1,000 sporozoites. The sporozoites migrate to the salivary glands where the 
cycle is completed when they are injected into another human being during a blood feed 
by the mosquito.  
 
1.5. Malaria epidemiology 
1.5.1. Plasmodium falciparum 
 Despite tremendous efforts for decades to control malaria, it remains a major 
public health problem 1, 34. Between 300 and 600 million episodes of P. falciparum 
infection occur each year 27. More than 70% of these cases occur in sub-Saharan Africa 
and 25% in South-East Asia 27. There is wide geographical variability in the incidence of 
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P. falciparum infection, even within sub-Saharan Africa with low incidence in southern 
Africa and in highland areas.  
 
Pregnant women and children under 5 years are at highest risk for severe disease. 
P. falciparum malaria kills 1.5 to 2.7 million people each year, of whom about 1 million 
are children under the age of 5 years in sub-Saharan Africa 1, 27, 35. P. falciparum infection 
indirectly accounts for an additional 5 to10% of neonatal and infant deaths due to its effect 
on birth weight 34. Other effects of P. falciparum infection include neurological sequelae 
such as hemiplegia following cerebral malaria, developmental abnormalities and impaired 
intellectual development as a result of repeated infections 36-40. P. falciparum infection 
also exacts an economic impact on both governments and families due to loss of 
productivity, time spent seeking treatment, and expenses arising from treatment and 
prevention costs 41, 42.  
 
1.5.2. Plasmodium vivax 
P. vivax is the second most important species causing human malaria, accounting 
for 70-80 million cases of malaria annually 29. It is responsible for over 50% of malaria 
cases outside Africa, notably South-East Asia, Central and South America and the Indian 
subcontinent. It also accounts for approximately 10% of malaria cases in eastern and 
southern Africa. The prevalence of P. vivax is very low in West Africa due to the presence 
of Duffy-negative blood group variants that limit erythrocyte invasion by the parasite 33. 
P. vivax infection mainly occurs in low transmission areas. Individuals living in these 
areas have little or no acquired immunity, and are at risk of symptomatic disease. P. vivax 
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parasites can remain dormant in the liver as hypnozoites. Reactivation of these liver forms 
may cause relapses of infection months after the initial infection. Tropical P. vivax strains 
usually begin to relapse within a month after the initial infection, whereas hypnozoites of 
temperate strains usually have an incubation period of several months 43. P. vivax 
exclusively invades reticulocytes (which typically constitute 1% of erythrocytes), and 
therefore achieves relatively low parasite densities compared to P. falciparum. Although 
rarely directly life-threatening, P. vivax can cause severe and debilitating febrile illness 33. 
Anemia is the most frequently observed pathological consequence of P. vivax malaria, 
both in acute and chronic infections.  
 
1.6. Symptoms of malaria 
The clinical manifestations of malaria appear approximately 7 to 14 days after an 
infectious mosquito bite. Symptoms are caused by the asexual erythrocytic stage of the 
parasite and are dependent on the species of plasmodium, the age and level of host 
immunity, and parasite species 33. The rupture of erythrocytes by merozoites releases 
toxins. These toxins directly induce the release of cytokines such as tumor necrosis factor-
α (TNF- α), and interleukin-1 (IL-1) from macrophages, resulting in symptoms of malaria 
33. Sequestration of parasitized erythrocytes within small vessels also contributes to the 
development of symptoms. The clinical presentation of malaria ranges from asymptomatic 
infection to rapidly progressive fatal illness. Acute malaria infection presents with 
nonspecific symptoms such as fever, headache, general body pains and anorexia. In non-
immune individuals, there is an increased risk for developing severe disease with 
prostration, confusion or drowsiness, which may evolve to loss of consciousness (cerebral 
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malaria), respiratory distress, anemia, severe jaundice and in rare cases, renal failure and 
pulmonary edema 44. Semi-immune individuals usually have mild symptoms or may 
remain asymptomatic. Repeated malaria infections frequently result in anemia.   
 
1.7. Diagnosis of malaria 
Microscopy remains the standard method of diagnosis in many malaria-endemic 
areas. It involves the examination of Giemsa or Field stained thick and thin blood films 
for the presence of intracellular (erythrocytic) parasites 45. Microscopy has the advantage 
of low cost, high sensitivity and specificity when used by well–trained microscopists. It 
also enables the differentiation of species of Plasmodium and quantification of parasite 
load. In most malaria-endemic areas where resources are scarce, diagnosis of malaria is 
based on clinical symptoms. Most of the symptoms and signs of malaria are nonspecific, 
and overlap with those of other febrile illnesses 46, 47. Clinical diagnosis of malaria can 
result in misdiagnosis and misuse of anti-malarial drugs. Other laboratory methods that 
have been developed include: the Quantitative Buffy Coat method which fluoresces 
parasites after an enrichment step for the infected erythrocytes; rapid diagnostic tests that 
detect the presence of P. falciparum specific histidine-rich protein-2 (HRP-2) or species-
specific parasite lactate dehydrogenase (pLDH); and polymerase chain reaction (PCR) 
based tests that identify parasite deoxyribonucleic acid (DNA) 48-51. All these methods 
have good results, some better than microscopy, but they are too expensive to be used in 
most malaria-endemic areas, and therefore have not replaced microscopy as the routine 
method for diagnosing malaria.   
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1.8. Plasmodium falciparum malaria in pregnancy  
1.8.1. Epidemiology  
Every year, at least 50 million women living in malaria-endemic areas are at risk 
of P. falciparum infection during pregnancy 1, 2. Women are at higher risk of acquiring P. 
falciparum infection when pregnant than when not pregnant, or when compared with adult 
males 52, 53. In areas of stable transmission, the risk of P. falciparum infection and its 
adverse effects is greatest in the first pregnancy and decreases with subsequent 
pregnancies 10,52,54,55. By contrast, in areas of low or unstable transmission, there is no 
difference in the risk of acquiring P. falciparum malaria infection, and the severity of 
adverse effects by parity, because women have little or no acquired immunity 56,57. The 
risk of P. falciparum infection also varies during the course of pregnancy. The prevalence 
of peripheral parasitemia is highest in the first half of pregnancy, then remains constant, or 
declines after mid-gestation, irrespective of transmission rates 54, 56. However, 
susceptibility to clinical malaria appears to be higher in both second and third trimesters 
of pregnancy 58. The increased risk for both acquiring P. falciparum infection and 
developing more severe disease persists for at least 60 to 70 days postpartum 58. Pregnant 
women with human immunodeficiency virus (HIV) infection have a higher prevalence 
and intensity of P. falciparum infection compared with non HIV-infected women 9, 10, 59-62. 
Women with HIV infection are also more likely to have symptomatic infection, and have 
an increased risk of malaria-associated adverse outcomes compared with women without 
HIV infection, irrespective of parity.  
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1.8.2. Pathophysiology 
Sequestration of parasites 
P. falciparum infection during pregnancy is characterized by the sequestration and 
multiplication of a distinct population of parasites in the intervillous spaces in the placenta 
63,64. The sequestration of infected erythrocytes (IEs) is mediated by adhesive interactions 
between parasite antigens on the surface of IEs and host molecules present on the 
microvascular endothelium 65-67. IEs isolated from placentas have a unique adhesion 
property that is different from parasites collected from non-pregnant individuals. They do 
not bind receptors such as CD36 and intracellular adhesion molecule (ICAM)-1, which are 
common adhesion receptors among isolates from non-pregnant hosts 33, 68. Instead, they 
bind chondroitin sulfate A (CSA) 69-72, hyaluronic acid (HA) 66,70,73,74 and non-immune 
immunoglobulin (Ig) 75. This uniqueness enables the parasites to evade immune responses 
acquired prior to the first pregnancy. The adhesion to CSA has been observed in IEs 
collected from infected placentae from several geographically distant sites, including 
Kenya, Thailand, Malawi and Cameroon 69-71, 76 suggesting that pregnant women are 
infected with parasites that express distinct adhesion receptors. Other processes could also 
be involved in the sequestration of IEs in the placenta, because histological examination 
of infected placenta tissue has shown that not all erythrocytes are adherent to the 
syncytiotrophoblast layer of the placenta 63, 64, 77. 
 
Cellular immune response  
The presence of P. falciparum malaria parasites in the placenta causes an 
infiltration of inflammatory cells in the intervillous space 77-80. The infiltrate consists 
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predominantly of monocytes, lymphocytes and macrophages and less commonly 
polymophonuclear cells. In some cases, the mononuclear cell infiltration in the 
intervillous space is intense, and is called massive chronic intervillousitis 80, 81. The 
placental mononuclear cells help to limit the infection in the placenta through 
phagocytosis of malaria parasites and the production of helper T cells (Th1) cytokines. 
The mechanism by which mononuclear cells are recruited into the placenta is not clearly 
understood. However, one study found an increased expression of messenger ribonucleic 
acid (mRNA) for β chemokines in malaria-infected placentae, which were positively 
correlated with monocyte densities in the placental intervillous spaces 82. Another study 
found that malaria-infected placentae produced high levels of migration inhibitory factor 
(MIF), a cytokine that activates macrophages and prevents the out migration of 
inflammatory cells 83. Therefore, the presence of chemokines and MIF may play a central 
role in the accumulation of inflammatory cells in malaria-infected placentae.  
 
Cytokines and chemokines  
Cytokines are also involved in the genesis of the inflammatory response to 
parasites sequestered in the placenta. The immune system is altered during pregnancy by 
suppression of the Th1 pathway, to accept the fetal allograft while maintaining host 
defenses against foreign antigens 84. P. falciparum infection induces a shift towards the 
production of Th1-type cytokines. Studies have found increased levels of TNF-α, 
interferon-γ (IFN-γ), interleukin factor-8 (IL-8) and interleukin factor-2 (IL-2) in malaria-
infected compared with non-infected placentae 82,85-88. These cytokines are produced by 
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the infiltrating macrophages and placental tissues and they attract and activate leukocytes 
in malaria-infected placentae 86,87.  
 
Humoral response 
Humoral immunity also plays a critical role in the protection against P. falciparum 
infection during pregnancy. Infection with novel P. falciparum antigens in the first 
pregnancy renders the repertoire of antibodies present before pregnancy ineffective 
against the placental parasites 76. Following exposure to P. falciparum during subsequent 
pregnancies, women residing in areas of stable malaria transmission develop antibodies to 
parasite surface antigens expressed on IEs that inhibit parasite adhesion to CSA and 
sequestration in the placenta 71,76,89-91. Sera from women in Asia and Africa cross-reacts to 
parasites from either continent, implying that the parasite-expressed proteins mediating 
adhesion to CSA have conserved epitopes targeted by anti-adhesion antibodies 76. Studies 
have shown that antibody responses to CSA-binding IEs are absent, delayed or present in 
low levels in primigravidae, but are present and in higher quantities in multigravidae 
74,76,91. These findings explain the parity specific epidemiology of malaria, the high 
susceptibility during first pregnancies, diminishing in subsequent pregnancies as women 
acquire specific antibodies against placental parasites. The presence of these antibodies 
has been associated with reduced prevalence 76 and density 92 of placental parasitemia 
among pregnant women. In Kenya, secundigravidae with serum anti-adhesion antibodies 
delivered babies that were on average 398g heavier, and 2 weeks more mature than babies 
born to secundigravidae without these antibodies 93. 
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Histological changes in the placenta 
Placental pathology occurs secondary to parasite sequestration and deposition of 
hemozoin (a heme-polymer formed as a by-product of hemoglobin breakdown) in the 
placenta, which causes the infiltration of mononuclear cells, and induction of pro-
inflammatory cytokines 77,78,80. Pathological changes are most marked in the intervillous 
space and to a lesser extent in the villous tissue. During early stages of infection, only 
parasites are detected in the intervillous space, mostly within maternal erythrocytes but 
occasionally in the cytoplasm of macrophages, or free in the intervillous space. Malaria 
parasites have also been detected in cord blood, but not in fetal erythrocytes or fetal 
structures 63,77. Chronic infection is diagnosed by the presence of hemozoin deposited 
within intervillous mononuclear cells, fibrin strands and trophoblasts 53,63,94. Typical 
histological changes that have been identified involving the villous surfaces include 
excessive syncytial knotting, apoptosis and disintegration of the villi, cytotrophoblast 
basement membrane thickening and occasional deposition of hemozoin in the 
cytotrophoblast or stroma 63,77-79,95-97. These changes may alter the placental materno-fetal 
exchange of oxygen and nutrients in the placenta thereby contributing to the malaria-
associated effect on fetal growth98.  
 
1.8.3. Diagnosis of malaria in pregnant women  
Malaria in pregnancy is diagnosed by microscopic examination of thick films 
prepared using peripheral blood samples during pregnancy, or placental blood samples at 
delivery, and histological examination of the placenta. Although maternal peripheral 
parasitemia has been used routinely to detect malaria during pregnancy, it has low 
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sensitivity because peripheral parasitemia may remain below levels of microscopic 
detection while parasites are harbored by the placenta 77,99. Different methods have been 
used to prepare thick films from placental blood, including scraping of the incision margin 
and washing of the placental tissue, and have been found to have similar sensitivities in 
detecting placental parasitemia 99. Histological examination of the placenta is the most 
sensitive indicator of maternal malaria infection 99,100, and enables classification of the 
infection as either active, past or chronic, and gives more information on placental lesions 
77,99.  
 
1.8.4. Complications of P. falciparum infection during pregnancy 
The symptoms and complications of P. falciparum infection during pregnancy 
depend on the intensity and stability of transmission, and preexisting maternal acquired 
immunity 101,102. Women living in areas where malaria transmission is low and unstable 
have little or no immunity. They are at risk of severe clinical disease, anemia, death, and 
adverse pregnancy outcomes including spontaneous abortions, still births, neonatal deaths 
and LBW 102,103. In moderate to high transmission areas, women have acquired partial 
immunity by the time they reach reproductive age 52,53. Therefore, they are not at risk for 
severe disease. The principal adverse effects of P. falciparum infection in these areas are 
maternal anemia and LBW.   
 
Maternal anemia 
Studies have consistently shown that P. falciparum infection during pregnancy 
increases the risk of maternal anemia 4,5,7. Each year as many as 400,000 pregnant women 
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in sub-Saharan Africa develop a severe anemia event as a result of P. falciparum infection 
3. Severe pregnancy-related anemia may result in maternal heart failure, and decreased 
ability to endure blood loss at delivery, with subsequent risk for death. The etiology of 
anemia is multi-factorial and is dependent on the age, immune status and the duration of 
infection 104. It is mediated through the hemolysis and phagocytosis of IEs by 
macrophages and natural killer cells, and poor bone marrow response 61. P. falciparum 
infection also induces biochemical modifications in the membranes of both infected and 
uninfected erythrocytes which mimic the erythrocytes’ normal aging process 105. 
Additionally, pro-inflammatory cytokines activate macrophages which release oxygen and 
nitrogen radicals that cause oxidative damage and membrane disruption to infected and 
uninfected erythrocytes 106. Consequently, there is enhanced removal of both infected and 
uninfected erythrocytes from the circulation by the host’s reticulo-endothelial system 
leading to anemia. The contribution of each of these factors in the development of anemia 
still remains unclear. Other factors that contribute to the development of anemia in women 
living in malaria-endemic areas include nutritional deficiencies, and infection with other 
parasites such as hookworm and HIV 107,108.  
 
Low birth weight 
Infection with P. falciparum during pregnancy also increases the risk for LBW 
109,110, which is the greatest risk factor for neonatal and early infant mortality 111,112. 
Malaria causes LBW through intrauterine growth retardation (IUGR) and/or premature 
delivery 103,113-116. Premature birth results commonly from symptomatic and severe 
malaria and therefore the major cause of LBW in low-transmission areas where acquired 
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immunity is low, whereas IUGR is the major cause of LBW in high transmission areas 
10,56,117. P. falciparum infection contributes an estimated 8 to 36% of premature deliveries, 
13 to 70% of IUGR, and 3 to 8% of infant deaths in malaria endemic areas 2,109,110. The 
actual mechanisms by which P. falciparum infection causes LBW still remain uncertain. 
Some factors that have been cited include maternal anemia 118, inadequate trophoblast 
invasion in early placentation 119, placental insufficiency due to mechanical compromise 
of the placental circulation arising from the thickening of the trophoblastic membrane 10,77, 
elevated pro-inflammatory cytokine levels 85,87, poor oxygen and glucose transfer from the 
parasitized erythrocytes and use of nutrients by macrophages sequestered in the placenta 
87. 
 
Congenital malaria 
P. falciparum–infected erythrocytes have been identified in umbilical cord blood. 
The prevalence of cord parasitemia varies widely according to geographical location. A 
survey of seven sites in Africa that examined cord blood microscopically found 
prevalence rates ranging from 0 to 23% 120. Studies that used more sensitive PCR assays 
identified P. falciparum parasites in 10%–32% of cord-blood samples, obtained from 
women in African 121,122, suggesting that the presence of malaria parasites in cord blood 
occurs with greater frequency than has been previously reported. Parasite-specific IgM 
and IgE have been detected in 11%–25% of cord-blood samples obtained from individuals 
in malaria-endemic areas. This suggests that some of the infections detected in newborns 
at delivery are acquired in the antenatal period because IgM does not cross the placenta 
during gestation 123,124. Infection also occurs during delivery, when mixing of maternal 
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and fetal blood takes place 125. The presence of parasitemia in babies born to immune 
women is often self-limited, and does not lead to congenital malaria due to the presence of 
placentally transferred maternal antibodies which provide protection, and activation of the 
fetal immune system by maternal malaria during gestation 126. However, congenital 
malaria does occur usually in babies born to non-immune women which can result in 
severe malaria and death 127.  
 
1.8.5. The effect of frequency and timing of P. falciparum infection 
during pregnancy on low birth weight and maternal anemia 
 
Studies have consistently shown that P. falciparum infection during pregnancy 
causes LBW 109,110, and maternal anemia 4,5,7. However, it is not clearly known whether 
the frequency and the stage of pregnancy at infection have a differential influence on these 
adverse outcomes. There are no published epidemiologic studies on the effect of 
frequency of P. falciparum infection during pregnancy on LBW and maternal anemia. 
Studies that have investigated the effect of timing of P. falciparum infection on placental 
pathology have reported that significant histopathologic placental malaria changes were 
more frequent in women with evidence of peripheral blood infection close to delivery 
compared with infection in early in the antenatal period128,129. Studies that have 
investigated the effect of time of P. falciparum infection on LBW have reported 
conflicting results. One study found that chronic infection and past malaria infections, but 
not acute infection were associated with an increased risk of LBW 7. In contrast, another 
study found that infants born to women who had active infection (parasites, monocyte 
pigment, with or without pigment in fibrin) had a higher risk of LBW than women who 
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had past infection 99. Studies that have investigated the association between timing of 
infection of P. falciparum and the development of maternal anemia have found no 
association between severe anemia and past placental malaria, but an association with 
active placental infection 7,99. These studies only diagnosed malaria at delivery, using 
placental histology to define the timing of infection during pregnancy, which could have 
resulted in misclassification of exposure. Therefore, there is need to conduct studies using 
more sensitive methods to identify the timing of infection during pregnancy and its effect 
on LBW and maternal anemia.  
 
1.8.6. Prevention of malaria in pregnant women 
 
Low transmission areas 
Pregnant women in these areas have little or no background immunity. Therefore 
the majority of infections are symptomatic and some may lead to severe and lethal 
infections. Prompt diagnosis and treatment of pregnant women during routine screening at 
antenatal visit is the mainstay of management 56. This reduces the risk of severe maternal 
disease and complications in the fetus.  
 
High transmission areas 
Most infections with P. falciparum in pregnant women in high transmission areas 
are asymptomatic, and are usually not diagnosed 130.The following prevention measures 
are, therefore, recommended: IPT, use of insecticide-treated nets, and effective case 
management 131.  
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Intermittent preventive treatment 
The first recommendation for the prevention of malaria in pregnant women in high 
transmission areas is IPT which refers to the periodic administration of treatment doses of 
anti-malarial drugs during pregnancy irrespective of the presence of parasites or clinical 
illness. The aim is to clear the placenta of parasites during the period of maximum fetal 
growth (24-36 weeks), and to clear peripheral parasitemia, allowing hematological 
recovery in the pregnant women. The WHO currently recommends that pregnant women 
living in stable malaria transmission areas should receive at least two doses of SP, 
beginning after quickening (first noted fetal movement) as part of the routine antenatal 
care service 8. Several studies have reported the advantages of providing IPT to pregnant 
women including reduction in the prevalence of peripheral and placental parasitemia, 
severe anemia in pregnant women 132-134, and increase in birth weight 9-11,17,19. In a study 
conducted in Malawi, the prevalence of placental malaria at delivery in women who had 
received SP was 10% compared with 47% of women who had not received SP 19 . In 
another study conducted in Malawi, women who were prescribed at least two doses of SP 
delivered babies with a mean birth weight 195g higher than women who had not received 
SP 11. In Kenya, IPT reduced the prevalence of peripheral parasitemia by 85%, and 
maternal anemia by 39% 132. Maximum benefit is derived from two to three doses of SP. 
However, even a single dose is beneficial. HIV impairs immunity to malaria therefore 
HIV-infected women require at least three doses of SP 9,135,136. As resistance to SP is 
increasing in many malaria endemic areas, concerns are being raised about its efficacy in 
preventing and treating malaria in pregnant women 137. 
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Insecticide treated bed-nets (ITNs) 
In addition to anti-malarial drugs, the WHO recommends the use of ITNs 
throughout pregnancy. ITNs act as a barrier reducing human-vector contact by physically 
excluding vector mosquitoes. The insecticide also repels, inhibits or kills any mosquitoes 
attracted to feed. Studies have reported conflicting results on the effect of ITNs on P. 
falciparum related adverse outcomes in pregnant women. Some studies found that ITNs 
reduced the risk of morbidity in pregnant women and LBW in areas of both stable and 
unstable malaria transmission 138-140.  Other studies found that ITNs had very little impact 
on maternal anemia, peripheral or placental parasitemia, or birth weight in areas with high 
transmission 141,142. A recent meta-analysis of trials that investigated the effect of ITNs on 
malaria in pregnancy found that use of ITNs was associated with significant reduction in 
peripheral and placental parasitemia, and LBW, and a non-significant reduction in 
maternal anemia 143. The uptake and use of ITNs has been low in many malaria endemic 
communities 131. The major reason for the low uptake rates in Africa has been high costs 
of buying and retreating the ITNs with insecticide 144-146. In an effort to make ITNs more 
affordable, several African countries have now taken the initiative to reduce tariffs on 
ITNs 131. 
 
Effective case management 
The third recommendation for preventing malaria during pregnancy in high-
transmission areas is prompt diagnosis and treatment of pregnant women with parasitemia 
even when women are not symptomatic 131. Additionally, all pregnant women in high 
transmission areas with severe anemia are presumptively treated with anti-malarials, even 
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in the absence of peripheral parasitemia and other symptoms of malaria. However, the 
options for treatment of malaria in pregnant women are few due to safety concerns for the 
fetus. The spread of resistance to the easily accessible, safe and affordable drugs such as 
CQ and SP is making the control of malaria in pregnant women more difficult. Currently 
there is a huge drive to start using artemisinin-combination therapies for treatment of 
malaria, and to delay the development of resistance 147. However, to date only a few 
studies that have investigated the safety and efficacy of these combination therapies in 
pregnant women 148-151.  
 
1.9. Non-falciparum malaria in pregnancy  
The role of P. vivax and its impact on the health of pregnant women and the fetus 
is not as well documented as P. falciparum infection. P. vivax malaria occurs mainly in 
low transmission areas (e.g. India, South America, and parts of South-East Asia) therefore 
women living in these areas have little or no immunity and consequently are at risk for 
symptomatic malaria infection and its adverse effects. The prevalence of P. vivax 
infection and parasite density increases during pregnancy due to the reticulocytosis of 
pregnancy (P. vivax exclusively invades reticulocytes) 33. P. vivax is less likely to relapse 
in pregnant women than in non-pregnant women, and is more likely to cause disease in 
multigravid than primigravid women 152. Sequestration of P. vivax in the placenta has not 
been observed. However, hemozoin has been detected in the placenta after infection 128. P. 
vivax infection during pregnancy increases the risk for LBW and maternal anemia, but to a 
lesser extent than P. falciparum 152,153.There is little information available on the effect of 
P. ovale and P.malariae infection during pregnancy.  
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1.10. Safety of anti-malarial drugs and pregnancy 
 CQ was the drug of choice for treatment and prevention of malaria in pregnant 
women in malaria-endemic areas until a decade ago when it was abandoned due to high 
levels of resistance 12,154. SP replaced CQ, and is currently the drug of choice for treatment 
and prevention of malaria in pregnant women in Africa. However, resistance to SP is also 
increasing 12 and there might be need to change to other anti-malarial drugs. Currently the 
options for malaria treatment and prevention in pregnant women are limited by safety 
concerns for the fetus. This is coupled with paucity of data on the safety of anti-malarial 
drugs because pregnant women have been systematically excluded from most malaria 
treatment trials for fear of toxicity to the fetus 155,156 (Table 1.1).   
 
1.10.1. Drugs considered safe during pregnancy 
Chloroquine 
CQ is a 4-aminoquinoline that has been used extensively for the treatment and 
prevention of malaria in pregnant women. Studies in pregnant women have shown that 
CQ, given in normal therapeutic doses, is safe and well tolerated even in the first trimester 
of pregnancy 157-160. In a study conducted in Malawi, among more than 2,500 women who 
had received CQ as weekly chemoprophylaxis throughout pregnancy, there were no 
reports of severe adverse outcomes such as increase in rates of abortions, stillbirths, or 
congenital abnormalities, only non-severe side effects such as itching, dizziness and 
gastrointestinal complaints were reported 115. Another study found no differences in the 
prevalence of birth defects in children born to 169 non-immune women who took CQ 
chemoprophylaxis throughout pregnancy compared with 454 births to women who had 
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not received CQ 160. Widespread resistance has now rendered CQ virtually useless against 
P. falciparum infections in most parts of the world. However, CQ is still useful for the 
treatment and prevention of malaria in pregnancy in places where resistance is still low 
such as West Africa, and for the treatment of P. vivax malaria.  
 
Sulfadoxine-pyrimethamine 
SP, a fixed dose combination of sulfadoxine (1500 mg) and pyrimethamine (75 
mg) is currently the drug of choice for treatment and prevention of malaria in pregnant 
women. It is considered safe for administration during the second and third trimester of 
pregnancy with no reports of toxicity in pregnant women, and no reports of increased risk 
of spontaneous abortions, still births or congenital defects,9,17,19,132,133. Although there is a 
theoretical risk of jaundice among premature babies born to mothers given sulfa drugs late 
in the third trimester 161, this has not been reported in studies where SP was administered 
for IPT 9,17,19,132,133. Published data on the use of SP during the first trimester of pregnancy 
are scarce 162. Two large case-control studies found evidence of teratogenic effects 
including cardiovascular and urinary tract malformations, and cleft defects when SP was 
given during the first trimester 163,164. When given weekly as prophylaxis to non-pregnant 
individuals, SP has been associated with rare and severe cutaneous reactions such as toxic 
epidermal necrolysis and Stevens–Johnson syndrome 165. However, there is no evidence 
that this risk is any greater in pregnant women 166. 
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Quinine 
Quinine is an alkaloid derived from the bark of the Cinchona tree. It is still the 
drug of choice for treatment of severe falciparum malaria in most countries 167. It is also 
used as first-line treatment in areas with multi-drug-resistant malaria in South-East Asia, 
and as second-line treatment for patients who fail to respond to the standard first-line 
therapy. Quinine is considered safe during all trimesters of pregnancy when taken at 
normal therapeutic doses 155,157. There was no evidence that quinine causes premature 
births or congenital abnormalities in Thailand in 178 women who were treated with 
quinine during pregnancy 168. In the same community, a retrospective study that recruited 
over 2,000 pregnant found that the risk of abortions in women who were treated with 
quinine during pregnancy was similar to the women who were not exposed to quinine 169. 
Quinine can cause adverse effects in pregnant women such as hypoglycemia 170,171, 
tinnitus and dizziness 168 and adherence is poor due to its bitter taste 150. When taken at 
very high doses during pregnancy, quinine has been used as an abortifacient 172 and 
studies have reported fetal optic and auditory nerve damage 173,174.  
 
Dapsone combinations 
Dapsone has been used extensively in pregnant women with leprosy without 
reports of severe adverse effects 175. Dapsone has also been used in combination with 
pyrimethamine (maloprim) 176-178 or chlorproguanil (Lapdap) 179 for chemoprophylaxis or 
treatment of malaria in pregnant women with no reports of adverse events or adverse birth 
outcomes in the pregnant women treated with either maloprim or Lapdap. Data is lacking 
on the safety of these drug combinations in the first trimester of pregnancy. 
 26
Agranulocytosis and severe hypersensitivity syndrome have been reported in non-
pregnant women receiving dapsone chemoprophylaxis using twice weekly dosing which 
is no longer recommended 180.  
1.10.2. Drugs with insufficient or questionable data on safety during 
pregnancy  
Mefloquine 
Mefloquine has been used both for treatment and prevention of malaria in pregnant 
women. However, the safety of mefloquine in pregnant women is still questionable 
because of conflicting results from different studies. Some studies have shown that 
exposure to mefloquine during pregnancy does not increase the risk of adverse pregnancy 
outcomes. In a study conducted in Malawi, the rates of stillbirths and abortions were 
similar between 451 pregnant women who had received 250mg of mefloquine weekly 
throughout pregnancy and 1,077 women who had received CQ prophylaxis 10. Only minor 
side effects such as dizziness and gastrointestinal complaints were reported by women 
who took mefloquine. In Thailand, 339 pregnant who were given either mefloquine 
prophylaxis or placebo against P. falciparum and P. vivax infections only reported minor 
side effects including transient dizziness 181. By contrast, other studies have found that 
exposure to mefloquine during pregnancy increases the risk of stillbirths. In a 
retrospective study of 3,587 pregnancies, of which 208 were exposed to mefloquine 
treatment in all trimesters of pregnancy, mefloquine was associated with an increased risk 
of stillbirth 169. Stillbirths were more frequent among those treated with mefloquine 
(4.5%) than those treated with quinine (1.6%), but the rates of other severe outcomes 
(abortion, congenital malformations, and neurological deficits) were similar between the 
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treatment groups. Among 53 female US military personnel in Somalia who inadvertently 
used mefloquine early in pregnancy, there were 17 elective abortions, 12 spontaneous 
abortions, 1 molar pregnancy, and 23 live births suggesting toxicity in the first trimester of 
pregnancy 182.  As a result of these conflicting reports, the current recommendation is not 
to use mefloquine in pregnancy unless there is a benefit for the pregnant woman 183. 
 
Amodiaquine 
Although the WHO currently recommends that amodiaquine can be considered 
safe for use against malaria in pregnant women 184, there is insufficient data available to 
be certain about its safety during pregnancy. There is no data available on the effect of 
exposure to amodiaquine in the first trimester of pregnancy 183. A review only identified 
six studies between 1948 and 1992 with a total of 300 pregnant women who had taken 
amodiaquine for prophylaxis or treatment in the second or third trimester of pregnancy 185. 
Only one these studies assessed the toxic effects of amodiaquine, but the rest of the 
studies did not report pregnancy outcomes. There have been reports of severe side effects 
such as agranulocytosis, granulocytopenia and hepatitis in studies when amodiaquine was 
used for chemoprophylaxis in non-pregnant adults 186,187. However, these severe adverse 
events have not been reported in studies when amodiaquine was used as treatment for 
malaria in non-pregnant adults 188.  
 
Malarone 
Malarone is a fixed combination of atovaquone and proguanil. There is limited 
data available on its use for treatment or prevention of malaria in pregnant women. 
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Clinical trials in non-pregnant patients, including areas of multi-drug resistance, have 
shown that malarone is well tolerated, and is highly efficacious in the prevention and 
treatment of uncomplicated P. falciparum malaria 189-193. Only minor adverse events 
including nausea, vomiting, headache and abdominal pain have been reported in these 
studies. At present, a few pharmacokinetic trials recruiting very small numbers of 
pregnant women have been conducted and have indicated that malarone is safe, and well 
tolerated when administered in the second or third trimester of pregnancy 194,195.  
 
Azithromycin 
Azithromycin is a broad-spectrum macrolide antibiotic that has been used 
extensively in pregnant women to treat sexually transmitted infections (STIs) and other 
infections, with no reports of severe adverse events 196-200. Azithromycin has just been 
recently found to have in vivo and in vitro activity against P. falciparum and P. vivax 
when administered alone, or in combination with other anti-malarial drugs 201-206. There 
are at present no published studies that have evaluated the safety and efficacy of 
azithromycin in the treatment or prevention of malaria during pregnancy. Azithromycin 
could prove to be an effective agent in the prevention of malaria during pregnancy, as it 
has generally been well tolerated by pregnant women treated for other infections.   
 
Artemisinin derivatives 
Artemisinin derivatives such as artesunate and artemether are extracts of the 
Qinghao plant (Artemisia annua). Artemisinin derivatives are currently the most effective 
anti-malarial drugs known. They have a rapid onset therapeutic effect. Compared to other 
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drugs, artemisinin derivatives reduce the gametocyte carriage, and thereby lower the risk 
of infectiousness 207. They have commonly been used in Asia and South America, and are 
increasingly being used in Africa to treat malaria in children and non-pregnant adults. 
There is limited human data on the use of artemisinin compounds in pregnancy, because 
most of the studies conducted on the safety of artemisinin derivatives have been in non-
pregnant individuals. Currently, there is controversy over the safety of artemisins in 
pregnancy. Studies from animal data have shown that artemisinin derivatives cause 
developmental toxicity and lethal effects in rodent embryos if given in the first trimester 
of pregnancy 208,209. There have been no reports of toxicity in pregnant women exposed to 
artemisinin derivatives during the first 148,210,211, second or third trimester of pregnancy 148-
150,210,212-214. However, the total number of women recruited in these studies was small and 
therefore the need for more studies to confirm the safety of the artemisinin derivatives 
when used during pregnancy. 
 
Combination therapy 
Currently, there is an increased drive to use the combination of artemisinin 
derivatives and other available anti-malarial drugs for the treatment and prevention of 
malaria in an attempt to delay the development and spread of drug resistance 147. The 
hypothesis is that the probability of parasites developing resistance to two 
chemotherapeutic agents with independent mechanisms of action is extremely low, in the 
order of once in 1012 treatments 215. Artemisinin derivatives rapidly decrease parasite 
density and gametocyte levels in treated patients, and, therefore, greatly reduce the level 
of infectiousness, and transmission of resistant strains 207. Trials conducted in children and 
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non-pregnant adults have found that combination regimens have higher efficacy than 
monotherapy with drugs that have already developed resistance 216. Among the 
artemisinin-based combinations, artesunate-amodiaquine and artemether-lumefantrine are 
the most developed, most marketed and currently most advocated for treating African 
children with uncomplicated P. falciparum malaria. Other studies have also examined the 
safety and efficacy of drug combinations not containing artemisinin derivatives in children 
with uncomplicated P. falciparum malaria. Combinations studied include SP-mefloquine, 
SP-CQ, chlorproguanil-dapsone (Lap Dap), malarone and lumefantrine-artemether (co-
artemether), with varying efficacy levels 217. However, very few trials have assessed the 
safety and efficacy of combination therapies in treating and preventing malaria in 
pregnant women 148-151. So far, these studies have shown that combination therapies are 
efficacious, well tolerated and safe. However, because of the small number of women in 
these studies, there is still need for more trials to confirm the safety and efficacy of 
combination therapies in treating and preventing malaria in pregnant women before they 
can be recommended for general use in pregnant women.  
 
1.10.3. Drugs contraindicated during pregnancy 
Drugs that are not recommended for use during pregnancy include primaquine, 
tetracycline, doxycycline, and halofantrine. Tetracycline and doxycycline cause 
discoloration of teeth, lenses and cornea and disturbances in skeletal growth 166. 
Primaquine is contraindicated in pregnancy because of the risk of hemolysis in individuals 
with glucose-6-phosphate dehydrogenase (G6PD) deficiency 162. Treatment with 
halofantrine has been associated with the lengthening of the QT interval and fatal 
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arrythmias in some individuals, and therefore needs electrocardiogram monitoring 166. 
This is impractical in most malaria-endemic areas due to the lack of resources, and 
therefore halofantrine is not recommended during pregnancy.  
 
1.11. Anti-malarial drug resistance 
1.11.1. Epidemiology of Plasmodium falciparum drug resistance  
P. falciparum has developed resistance to nearly all anti-malarials in current use 
except the artemisinin derivatives 218. The prevalence of resistance to any single anti-
malarial drug varies greatly according to geographical location 12. Comparison of the 
current prevalence of resistance across different regions is complicated by the variability 
in the period of follow-up, definition of outcomes and type of subjects recruited into 
efficacy trials. Drug resistance poses a great challenge in the control of malaria, because 
there are few cheap alternative anti-malarial drugs available. It has led to rising malaria-
related morbidity and mortality, especially in East Africa 219,220. Resistance may be 
generated independently or spread across areas. There is molecular evidence of a single 
origin of resistant alleles to pyrimethamine in South-East Asia, which were imported into 
East Africa and are now spreading across the African continent 221,222. Conversely, CQ 
resistance evolved independently in different areas, through multiple evolutionary 
pathways 223,224.  
 
Chloroquine 
P. falciparum resistance to CQ appeared in the late 1950s in Thailand and 
Cambodia, and in the 1970s in New Guinea and eastern sub-Saharan Africa. Clinically 
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evident resistance to CQ in P. falciparum is nearly universal and now predominates 
South-East Asia, South America and Africa 12,154, (Figure 1.3). A review of in vivo studies 
conducted between 1996 and 2002 with follow-up periods ranging from 7 to 28 days, 
found that parasitological failure rates varied from 10 to 98% in Africa, 38 to 91% in 
South-East Asia, 23 to 38% in the Pacific region and 46 to 77% in the Indian subcontinent 
154. Many countries have abandoned the use CQ as first line therapy. The only exceptions 
are North-West of Panama in Central America, Haiti and the Dominican Republic, and the 
Middle East where the magnitude of CQ resistance is still the subject of investigation 154. 
 
Sulfadoxine-pyrimethamine 
Resistance to SP, the main alternative to CQ emerged rapidly after its deployment 
in Asia. Currently, high-level resistance is found in a large part of South-East Asia, 
Southern China and the Amazon basin 12, (Figure 1.3).  The parasitological failure rates 
reported by in vivo studies between 1996 and 2002, with follow-up periods ranging from 7 
to 28 days, varied from 5 to 67% in Asia, and from 6 to 20% in South America 154.In 
Africa, resistance to SP also developed quickly soon after it was introduced in countries 
where CQ treatment was failing 225. Currently resistance has been reported in many parts 
of Africa. The clinical failure rates with at least 14 days of follow-up have ranged from 0 
to 76% 225.  
 
Quinine 
Clinical resistance to quinine monotherapy occurs in South-East Asia and Western 
Oceania 149,225 and is less frequent in South America 226 and Africa 227. For example, the 
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clinical failure rates after treatment of acute uncomplicated P. falciparum malaria over 7 
days with a follow-up of 14 days were 0% in Gabon, 4.8-5.5% in Equatorial Guinea and 
6.3-9.3% in Sudan where follow-up was for 28 days 228-230.  
 
Mefloquine 
Mefloquine resistance was first observed on the Thai-Cambodian and Thai-
Burmese borders in the late 1980s, and monotherapy is no longer effective there 231,232. 
Resistance is believed to have spread from these areas to India and Bangladesh 233. A few 
cases of resistance have been reported in the Amazon basin and South America 225,234, and 
in vitro studies have reported resistance in Africa 235,236. Overall, clinical mefloquine 
resistance outside South-East Asia is rare.  
 
Amodiaquine 
Despite cross-resistance between amodiaquine and CQ, amodiaquine is generally 
more effective than CQ against CQ-resistant strains of P. falciparum 237. Moderate-to-high 
levels of amodiaquine resistance have been reported from Papua New Guinea, East Africa 
and the Amazon Basin 225. However, this drug continues to be efficacious as a single drug 
in most of West and Central Africa and on the northern Pacific Coast of South America 
where, in some countries, it is used in combination with sulfadoxine-pyrimethamine 225. 
 
Artemisinin derivatives 
Resistance to artemisinin derivatives has been induced in murine models 238-
240.Confirmed resistance to the artemisinin derivatives has not been reported in humans. 
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However, recrudescence among patients receiving a short course (less than 5 days) of 
therapy has been observed 241. Recrudescence is thought to be due to pharmacological 
factors such as taking inadequate doses and host metabolism. There is no convincing 
evidence yet that recrudescence in humans is due to parasite resistance.  
 
Multi-drug resistance 
Multi-drug resistance which is defined as resistance to three or more anti-malarial 
compounds from different chemical classes occurs in South-East Asia, particularly along 
the borders of Thailand with Burma and Cambodia, and in the Amazon basin 12. In these 
areas, P. falciparum parasites are resistant to CQ, mefloquine, SP and to a lesser extent 
quinine. Countries in East Africa are at risk of multi-drug resistance because resistance to 
CQ and SP is already widespread.  
 
1.11.2. Epidemiology of Plasmodium vivax drug resistance  
Overall, P. vivax parasites are sensitive to most anti-malarial drugs. There have 
been reports of CQ resistance to P. vivax from many geographic locations worldwide, but 
they have been not been a very large scale. Resistance is prevalent and increasing in some 
areas, notably Oceania, India, Indonesia, Brazil, Papua New Guinea and Myanmar 32. 
Monitoring of drug resistance to P. vivax is confounded by the relapse of vivax malaria. In 
some cases, it is not possible to distinguish clearly a recrudescence from a relapse when 
using available genotype methods, because strains causing relapse and recrudescence 
might be derived from the same initial infection 242,243. Consequently, CQ-resistant P. 
vivax parasites might be more common than has been reported.  
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1.12. Molecular markers for anti-malarial drug resistance   
Resistance to anti-malarial drugs occurs as a result of spontaneous mutations, or 
gene amplification in the parasite genome 244. These mutations affect the structure and 
activity, at the molecular level, of the drug target in the malaria parasite or access of the 
drug to its target, thereby interfering with the parasite’s susceptibility to a drug. Molecular 
markers for resistance have been identified for SP 245, CQ 246, mefloquine 247, and 
atovaquone 248. Markers for most of the other anti-malarial drugs have not been identified 
because mechanisms of resistance are not yet understood at the molecular level.  These 
molecular markers are beginning to be applied as tools for surveillance of resistance but 
are, at present, still primarily used as research tools.   
 
Chloroquine 
CQ acts by increasing its concentration in the parasite’s digestive vacuole of the 
intra-erythrocytic trophozoite. In this organelle, CQ inhibits hemoglobin degradation and 
forms complexes with hematin. A mutation at codon 76 of the P. falciparum CQ-
resistance (pfcrt) gene, which encodes for a trans-membrane protein located in the 
digestive vacuole, has been associated with resistance to CQ 224,246,249,250. This mutation 
alters the accumulation of CQ in the digestive vacuole. Clinical studies have confirmed 
the presence of this mutation in individuals who experienced treatment failure, after 
treatment with CQ 246,251,252.  However, this mutation has also been found in CQ-sensitive 
isolates, indicating that other mutations may also be involved in the development of 
resistance 251,253. Polymorphisms in P. falciparum multi-drug-resistance gene 1 (pfmdr1) 
modulate CQ resistance in mutant pfcrt-harboring parasites in vitro 254. However, their 
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role in in vivo resistance has not been established 246. Currently, mechanisms of P. vivax 
resistance to CQ are not well understood, but appear to differ from those for P. falciparum 
255. The mutation of the pfcrt gene that is essential for CQ resistance in P. falciparum is 
not present in P. vivax CQ resistant strains. 
 
Sulfadoxine-pyrimethamine 
Pyrimethamine interrupts deoxyribonucleic acid (DNA) replication in the parasite 
by competitively inhibiting the enzyme dihydrofolate reductase (dhfr) in the folate 
synthesis pathway, which is essential for the synthesis of pyrimidines 256. Point mutations 
at codons Asn-108, Arg-50, Ile-51, Arg-59 and Leu-164 in the dhfr gene alter the active 
binding site cavity of the drug to the enzyme 256. The point mutation at Asn-108 in the 
dhfr gene appears to be the key mutation that confers P. falciparum resistance to 
pyrimethamine 257,258. Additional point mutations in codons Arg-50, Ile-51, Arg-59 and 
Leu-164 are known to progressively increase the degree of resistance 245,259. These 
mutations have been strongly associated both with in vitro and in vivo resistance of P. 
falciparum to SP 22,260,261. Long-term in vitro observations have suggested that in addition 
to these mutations, gene amplification of the dhfr gene is also an important mechanism of 
pyrimethamine resistance 262.Two mutations, Arg-58 and Ser-117, have been identified as 
key for P. vivax resistance to pyrimethamine 263.  
  
Sulfadoxine inhibits the enzyme dihydropteroate synthase (dhps), which is 
essential in the early pathway of folate synthesis in the parasite. Mutations in the dhps that 
have been associated with P. falciparum in vivo and in vitro resistance include Ala-436, 
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Phe-436, Gly-437, Lys-540, Gly-581, Thr-613 and Ser-613 22,261,264-266. It is unclear which 
one is the key mutation, as a mutation at codon 108 is in dhfr.   
 
To date, more than 25 different combinations of dhfr and dhps mutant alleles in P. 
falciparum have been observed in field isolates 266. One study showed that patients 
infected with parasites carrying the dhps Gly-437/Glu-540 double mutant and the dhfr 
triple Asn-108/Ile-51/Arg-59 mutant had a high relative risk of treatment failure compared 
to those infected with parasites carrying the dhfr  triple mutant alone 261. This quintuple 
mutant (3 dhfr and 2 dhps mutations) has been suggested as a relevant molecular marker 
for failure of SP treatment of uncomplicated P. falciparum cases 245. In population 
monitoring, the presence of mutations at codon 59 of the dhfr gene and codon 540 of the 
dhps gene have been strongly predictive of the quintuple mutation 267,268. Treatment 
failure can, however, occur in the presence of fewer than five mutations on the dhfr and 
dhps genes 259,265. 
 
Mefloquine and artemisinin derivatives 
Mutations and gene amplification of the pfmdr1 have been implicated in the 
resistance to several drugs. Studies in Thailand found that increased gene copy number of 
the pmdfr1 gene was associated with in vivo and in vitro resistance to mefloquine 247,269. 
Amplification of pmdfr1 gene in P. falciparum and P. yoelli appears to be common 
genetic mechanism for in vitro resistance in artemisinin derivatives 238-240. These in vitro 
mutations have not been associated with clinical failure to artemisinin derivatives 270,271.  
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Atovaquone 
Atovaquone has been shown to inhibit the cytochrome bc1 (CYT bc1) complex of 
the electron transport chain of malaria parasites 272. Resistance to atovaquone results from 
point mutations in the cytochrome b gene (cytB) codon 248. This mutation induces an 
approximately 10,000 fold increase in the atovaquone IC50 in vitro tests.  
 
1.13. Factors contributing to the development of drug resistance 
The development and spread of drug resistance is influenced by an interaction 
between drug, host, parasite, vector and environmental factors.   
1.13.1. Parasite characteristics 
Vector capacity, in-vector recombination of genes and fitness of the mutated 
parasites are all important factors that influence the speed at which resistance emerges and 
spreads 154. In Sri Lanka, researchers found that patients with CQ-resistant malaria 
infections were more likely to have gametocytemia than those with sensitive infections 273. 
Gametocytes carrying resistant genes have also been shown to be more infectious to 
mosquitoes 274. The species of Plasmodium also influences the transmission of resistance. 
P. falciparum gametocytes form after the appearance of symptoms and drug treatment, 
and hence favor the transmission of resistant genotypes. By contrast, early P. vivax 
gametocytogenesis allows the parasite to be transmitted before the symptomatic stage of 
the disease and anti-blood-stage chemotherapy. The mechanism of resistance also 
determines the rate of development of resistance. It develops rapidly when it is conferred 
by a low number of mutations, as was noted for atovaquone 189.  
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1.13.2. Individual characteristics 
 Age, irrespective of prior exposure to malaria assists in the ability to clear 
parasites following treatment. Studies have shown that adults from a malaria-free area of 
Indonesia who migrated to a malaria-endemic areas acquired immunity significantly more 
rapidly than children did 275. The level of acquired immunity in individuals also plays a 
major role in the development of drug resistance. Individuals with immunity against 
malaria increase the efficacy of chemotherapy because they can clear parasites despite the 
presence of resistance 276-279. However, individuals who do not have immunity generate a 
response that is not as effective as the specific immunity elicited by repeated infections. In 
addition, individuals with no immunity usually have high parasite levels and therefore 
require longer periods to clear the parasites 280. This increases the survival time of 
parasites and facilitates the development of resistance 215. Furthermore, infection in 
individuals with no prior immunity usually progresses to symptomatic disease. Therefore, 
these individuals are treated more often than are individuals with acquired immunity, 
increasing the probability of the selection of resistant genotypes 244.  
 
1.13.3. Anti-malarial drug properties and drug-use practices 
 A number of behavioral and pharmacokinetic factors affect the probability of 
parasites encountering sub-therapeutic levels of anti-malarial drugs. Drugs that have a 
long elimination half-life such as mefloquine and SP exert substantial residual selection 
for resistant strains when the drug persists at sub-therapeutic concentrations in the plasma, 
especially in areas with high transmission rates where individuals are at risk of getting 
frequent infections 281,282. Anti-malarial drugs such as atovaquone and lumefantrine are 
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lipophilic and hydrophobic and are variably absorbed such that there might be inadequate 
blood concentrations even after taking the full treatment dose 244,280. Incorrect dosing, 
non-compliance with the duration of the dosing regimen, and use of poor drug quality all 
result in sub-therapeutic drug levels which increase the probability for the selection of 
resistance strains 233.  
 
Pharmacodynamic properties of anti-malarial drugs also influence the rate of 
development of resistance. Anti-malarial drugs that reduce the parasite concentration 
rapidly such as artesunate reduce the parasite biomass, and the selective pressure for the 
emergence of resistant mutants 215. The effect of anti-malarial drugs on gametocyte 
carriage rate also plays an important role in the development and spread of resistance. SP 
increases the gametocyte carriage rate after treatment, hence increasing the risk of 
transmission of resistant strains if present in the host to the mosquitoes and the community 
283. However, artemisinin derivatives reduce the gametocyte carriage, and thereby lower 
the risk of infectiousness and risk of transmission of resistant strains 207. 
  
1.14. Monitoring drug resistance 
Monitoring of anti-malarial drug resistance is an essential part of managing 
malaria at a country level. The rapid spread of anti-malarial drug resistance over the last 
few decades has increased the need for monitoring to allow early detection of changing 
pattern of resistance, and to ensure proper management of cases of malaria. There are 
three main ways in which drug resistance is monitored: in vivo tests, in vitro tests, and 
using molecular markers.  
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1.14.1. In vitro tests 
  Parasites obtained from patients are mixed with growth medium, and the growth in 
drug-exposed cultures is measured relative to a drug-free control. Several tests have been 
developed that measure the effect of anti-malarial drugs on the growth and development 
of parasites by measuring the inhibition of schizont maturation, the percentage change in 
infected red blood cell in the culture and the levels of pLDH or (HRP-2) 284. The 
advantage of this method is that it measures the intrinsic sensitivity of P. falciparum 
parasites to anti-malarial drugs without the confounding factors such as host immunity 
and drug metabolism that influence in vivo tests 218. However, this method requires a lot of 
technical expertise, and is expensive, making it difficult to be adapted into routine field 
work. It is also difficult to culture isolates from patients with low-level parasitemia and 
individuals who had prior anti-malarial therapy 218. Drugs that require host conversion into 
active metabolites cannot be tested. Variations in techniques preclude comparison of 
results from different areas 154. Furthermore, there have been inconsistencies reported in 
the correlation between the results of therapeutic efficacy and in vitro tests 26. 
 
1.14.2. Molecular markers 
Some mutations in the parasite genome have been associated with anti-malarial 
drug resistance when compared with in vitro and in vivo tests 257,261,265,285. Molecular tests 
use PCR methods to indicate the presence of mutations encoding biological resistance to 
anti-malarial drugs. This method enables investigators to distinguish between reinfection 
and recrudescence, study many isolates in a short time, and the collection, storage and 
transportation of specimens is easier than when conducting in vitro studies 218. The 
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method also eliminates the possible bias from host factors which arise from in vivo tests, 
and selective pressure from cultures in vitro tests 218. However, PCR methods cannot 
distinguish gametocyte DNA from that of asexual forms present in the blood and 
therefore, acute malaria could be classified as recrudescence 154. It is also hard to compare 
results from different laboratories due to lack of standardization in specimen collection 
protocols, DNA extraction, PCR amplification techniques for molecular markers and 
interpretation 286,287. Furthermore, molecular markers of resistance have not been 
identified for all anti-malarial drugs. There is also need to validate with clinical data 
before the results can be correctly interpreted.  
 
1.14.3. In vivo tests 
 The gold standard for monitoring parasite resistance is the in vivo test 288. This test 
involves recruiting symptomatic and parasitemic patients, treating them with the drug of 
interest, and following them for 28-63 days for evidence of treatment failure (i.e. return of 
parasitemia with or without fever) 218. The WHO has developed a standardized protocol to 
enable comparison of results from different countries, and to include malaria low-
transmission areas 289. Originally the follow-up period was restricted to 14 days in high 
transmission areas, because it was considered unlikely in such a short period to have a 
new infection 288. However, this short follow-up period may underestimate the rate of 
recrudescence in drugs such as artesunate where the majority of treatment failures may 
occur after 14 days 290-292. For  treatment with drugs such as amodiaquine, CQ and SP, a 
28-day follow-up is considered appropriate; follow-up periods of 42 days and 63 days are 
recommended for artemether-lumefantrine and mefloquine, respectively 293. Because of 
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the longer follow-up periods, it is recommended that these studies should be accompanied 
by molecular genotyping using PCR techniques to distinguish recrudescence from 
reinfection 294.The advantage of in vivo tests is that they accurately portray the response 
which involves a complex interaction between the parasites, the drug and the host 
response, and the results are easily interpretable and appeal to policy makers 154. However, 
diminished therapeutic efficacy can be masked by parasite clearance in individuals living 
in areas with high transmission with acquired immunity 277,295.   
 
1.15. Distinguishing recrudescence from re-infection 
 Decisions regarding drug policy rely largely on the results of in vivo studies that 
assess clinical and parasitological outcomes after therapy. These studies are limited by 
their inherent inability to distinguish recrudescence from new infection when parasites are 
detected after therapy. Molecular genotyping is being used increasingly to help distinguish 
recrudescence from re-infection when conducting in vivo studies 259,290,291,296. There are 
three genes that are commonly used as markers due to their great polymorphism, both in 
length and sequence: merozoite surface protein 1 and 2 (msp1 and msp2) and glutamate-
rich protein (GLURP) located on chromosomes 9, 2 and 10, respectively 294,297. Extensive 
polymorphism makes it highly unlikely for a patient in an area of intense transmission to 
be re-infected, during the follow-up period, with a parasite identical to the infecting 
parasite at baseline. The probability that an isolate is identical in two randomly selected 
samples decreases significantly as the number and polymorphism of the genetic markers 
used increases 296. If the parasites are genetically different, it is assumed that it is a new 
infection, and if they are identical it is assumed to be a recrudescence. However, these 
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methods also have limitations. Some genotypes, representing a minority of the parasite 
population may not be detected at recruitment, but could be detected during the follow-up 
if they are resistant and if all the other sensitive parasites have been eliminated by the drug 
action. Such an infection would be wrongly classified as a new infection, overestimating 
the efficacy of the study drug 154. Conversely, in places where there are few circulating 
parasite genotypes, a new infection might be genotypically similar to the initial infection 
eliminated by the drug 297. 
 
1.16. Summary and Justification 
Malaria infection during pregnancy is a major public health problem, causing 
maternal anemia and low birth weight in malaria endemic areas. However, the importance 
of timing and frequency of P.falciparum infection during pregnancy on these adverse 
outcomes is still poorly understood. To reduce the risk of these adverse outcomes, women 
are treatment presumptively with two doses of SP during pregnancy. Resistance to SP is 
increasing in most malaria-endemic areas and information on the safety of most of the 
available anti-malarial drugs during pregnancy is lacking.  
 
We used data longitudinal observational study that performed took serial 
measurements of peripheral parasitemia during pregnancy, and peripheral and placental 
parasitemia at delivery to accurately identify the timing and frequency of P. falciparum 
infection during pregnancy and investigate their effect on the risk LBW and maternal 
anemia. 
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To add to the existing body of knowledge on the safety and efficacy of anti-
malarial drug treatments on pregnant women, we used data from a clinical trial that 
assessed the efficacy and safety of azithromycin and artesunate combined with SP as 
treatment for malaria in pregnant women in the second and third trimester of pregnancy. 
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Figure 1.1. The global distribution of Plasmodium species 
 
 
       Adapted from, Lancet Infect Dis 2004; 327–36 
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Figure 1.2. The transmission and life cycle of Plasmodium species 
 
 
       Adapted from Trends in Parasitology (2002) 18, 411-418 
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 Figure 1.3. The world distribution of reported resistance to chloroquine and 
sulfadoxine-pyrimethamine by Plasmodium falciparum, 2004 
 
 
 
         Source: WHO, 2004
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 Table 1.1.The use and safety of anti-malarial drugs during pregnancy 
 
Drug Treatment 
of malaria 
Prevention 
of malaria 
First 
trimester 
Second 
trimester 
Third 
trimester 
 
Conclusion 
 
Chloroquine157-160
 
9 
 
9 
 
9 
 
9 
 
9 
Safe in the all trimesters of 
pregnancy 
 
Sulfadoxine-pyrimethamine 
9,19,132,163,164
 
9 
 
9 
 
X 
 
9 
 
9 
Safe in the second and third 
trimester of pregnancy 
 
Quinine 155,157
 
9 
 
X 
 
9 
 
9 
 
9 
Safe in all trimesters of 
pregnancy 
 
Dapsone-pyrimethamine  176-178
 
9 
 
X 
Limited data 
available 
 
9 
 
9 
 
Limited data available 
 
Dapsone-chlorproguanil 179
 
9 
 
X 
Limited data 
available 
 
9 
 
9 
Limited data available 
 
Mefloquine 10,169,181,182
 
9 
 
9 
Limited data 
available 
 
9/X 
 
9/X 
 
Conflicting results  
 
Amodiaquine 185  
 
9 
 
X 
Limited data 
available 
 
9 
 
9 
 
Limited data available 
 
Malarone  194,195
 
9 
 
X 
Limited data 
available 
Limited 
data 
available 
Limited 
data 
available 
 
Limited data available 
 
Azithromycin 201-206
 
9 
 
X 
 
9 
 
9 
 
9 
 
Limited data available 
 
Artesunate 148,148-150,208-210,210-214
 
9 
 
X 
 
Not known 
 
9 
 
9 
 
Limited data available 
 
Halofantrine 166
 
X 
 
X 
 
X 
 
X 
 
X 
 
Not safe 
 
Tetracycline/Doxycycline 166
 
X 
 
X 
 
X 
 
X 
 
X 
 
Not safe 
 
Primaquine 166
 
X 
 
X 
 
X 
 
X 
 
X 
 
Not safe 
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9- safe: X- not safe 
 
  
CHAPTER 2 
 
OBJECTIVES, STUDY DESIGN, AND METHODS
 
2.1. Specific Aim I 
 
To investigate the effect of the timing and frequency of P. falciparum infection 
during pregnancy on low birth weight and maternal hemoglobin concentration 
 
2.1.1. Rationale  
While it is clear that P. falciparum infection during pregnancy  increases the risk 
for  low birth weight (LBW) and maternal anemia 1-7, it is not known whether this effect 
depends on the time at which the infection occurs during pregnancy. It has also not been 
established whether the number of episodes of P. falciparum infection experienced during 
pregnancy determine the severity of these malaria-related adverse outcomes. Most 
previous studies have only examined the association between P. falciparum infection and 
these adverse outcomes at one point in time during pregnancy 4-6,8. They have commonly 
used placental infection as a standard indicator of malaria infection during pregnancy. 
However, this indicator, as any single measure, may not accurately describe the evolution 
of infection status throughout pregnancy. Furthermore, some of the studies have limited 
recruitment to primigravidae 9. Although the risk of malaria infection and its 
complications is highest in primigravidae 2, P. falciparum infection in multigravidae is not 
infrequent, and still poses a significant risk for severe anemia and LBW. In most malaria-
endemic areas, resources are limited, women do not have frequent access to antenatal care 
services, and there is usually a shortage of drug supplies. The effect of frequency and 
timing of infection can provide information about the crucial risk period during pregnancy 
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relative to malaria infection when intervention would have the most important effect. This 
would aid health policy makers to adapt existing malaria prevention programs to be most 
effective in preventing the adverse effects of malaria during pregnancy.  
 
2.1.2. Objectives 
 
1. The primary objective was to investigate the effect of the frequency of episodes of P. 
falciparum infection experienced during pregnancy on the risk of low birth weight and 
maternal anemia. 
2. The secondary objective was to investigate the effect of timing of P. falciparum 
infection during pregnancy on the risk of low birth weight and maternal anemia.  
 
2.1.3. Primary hypotheses 
 
1. The risk of LBW and maternal anemia increases with the number of episodes of P. 
falciparum infection detected during pregnancy 
 
2. P. falciparum infection in the third trimester of pregnancy increases the risk of LBW 
and maternal anemia more than infection in the second trimester of pregnancy. 
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 2.1.4. Study design and methods 
Study site and population 
The study was conducted at Mpemba and Madziabango Health Centers in Blantyre 
district, in the southern region of Malawi. Blantyre District covers 2,012 km2 with a 
population of approximately 950,000 people 10. Sulfadoxine pyrimethamine (SP) has been 
the standard treatment for uncomplicated malaria and presumptive treatment for most 
fevers since 1993 at all health facilities, and the private sector in Blantyre. IPT is routinely 
available as part of the antenatal care in Malawi. The two health centers have maternity 
beds for delivery of low risk pregnancies, 4 full-time and 9 part-time nurses, and a malaria 
microscopy laboratory with a trained medical technologist. There are 18 traditional birth 
attendants (TBAs) that take care of births that occur in the community. Approximately 
200 pregnant women have their first antenatal visit every month at the 2 health centers. 
Women with high risk pregnancies are referred to Queen Elizabeth Central Hospital 
(QECH), a tertiary hospital located about 10 km away from the health centers for 
management and delivery. 
 
Study recruitment and enrollment   
All pregnant women attending routine antenatal care at the two health facilities 
were eligible to participate in the study. A total of 2,462 women were recruited over a 
period of 15 months. Written or witnessed verbal consent was sought from the women for 
participation in the study prior to enrolment. Women who gave consent to participate in 
the study were interviewed using a standardized questionnaire to obtain demographic 
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information, past obstetric history and factors associated with use of malaria prevention 
measures including use of ITNs and anti-malarial drugs during the current pregnancy. The 
women also received routine antenatal assessment which included abdominal 
examination, height, weight, temperature, blood pressure and fetal heart rate 
measurements, and examination for the presence of high risk factors for the pregnancy. 
Gestational age was estimated by a midwife using the last menstrual period and the 
symphysis-fundal height. A venous blood sample was collected for syphilis testing (in 
accordance with the Malawi government national policy), maternal hemoglobin 
concentration estimation and preparation of thick blood films. The women were given a 
dose of SP for IPT under direct observation by the antenatal clinic personnel. Antenatal 
records were checked before administering SP to ensure that the women had not received 
SP in the previous 4 weeks prior to enrolment. Study participants were given a study 
number to retain until delivery for easy identification during follow-up.  
 
Follow-up 
The follow-up visits were scheduled according to the normal antenatal routine 
care. Depending on the gestation age at enrolment, women were seen at these time points: 
12 weeks, 26 weeks, 32 weeks and 36-38 weeks age and at delivery. At these scheduled 
visits, women received routine antenatal care. This included abdominal examination, 
blood pressure and fetal heart rate measurement. A standardized questionnaire was used to 
obtain information on history of malarial illnesses, and use of anti-malarial drugs outside 
the study setting. A peripheral blood sample was obtained for examination of thick films. 
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The women were given another dose of SP, at least 4 weeks after the initial dose 
according to the Malawi national policy schedule.  
 
Delivery  
The majority of women in the study area deliver at the health centers. However, 
there are some women who deliver in the community under the supervision of TBAs. For 
women who delivered at the health center, blood samples were obtained to measure 
maternal hemoglobin concentration, and to prepare peripheral, placental and cord thick 
films. Newborns were weighed within 24 hours of delivery using a digital scale to the 
nearest gram. A system was set up such that community nurses and TBAs were able to 
identify women enrolled into the study who delivered at home. TBAs were trained to 
prepare peripheral, placental and cord blood smears from women who delivered in the 
community, and to forward the samples to the clinics through community health workers. 
Newborns delivered in the community were weighed using color coded scales that 
indicated green if the baby weighed more than 2500 grams and red if the baby weighed 
less than 2500 grams.  
 
Laboratory procedures 
Diagnosis of malaria 
Malaria diagnosis was performed using microscopy, which remains the standard 
for laboratory confirmation of malaria. Thick films were prepared from blood obtained 
from the subjects at enrollment, subsequent visits and at delivery. The slides were air 
dried and then flooded with buffered water (pH 7.2) for 3-5 minutes to allow the lyses of 
red blood cells. This was followed by staining by flooding the slide with 10% phosphate-
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buffered Giemsa for 30 minutes, and then rinsing with tap water and air-drying 11. Slides 
were examined under a microscope using a magnification of 100 x oil immersion 
objective to detect and quantify parasitemia. Assuming a standard white blood cell count 
of 6,000 per microliter, the number of parasites present until 200 leucocytes were counted, 
and multiplied by 30 to estimate the parasite density per microliter of blood. A thick film 
was considered negative if no parasites were detected after examining 100 microscopic 
fields each containing approximately 20 white blood cells. All thick films were examined 
by two skilled microscopists and any discrepancies (positive versus negative or more than 
25% difference in parasite density) were solved by repeating the readings. 
 
Hemoglobin concentration 
Hemoglobin concentration was measured using a HemoCueÒ machine (HemoCue 
Incorporated, Angelholm, Sweden). A sample of 10µl of blood obtained from the study 
participant was pipetted into a cuvette and inserted into the machine. The microcuvettes 
were stored at 59-86°F (15–30°C) in a dry place and the containers were closed at all 
times.
 
Human subjects 
IRB approval for the study was granted by the University of North Carolina and 
the College of Medicine, University of Malawi. The study nurses ensured that all the 
study procedures were explained, before obtaining informed consent. Personal 
information was not included on study documents and samples to ensure confidentiality. 
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Blood samples were obtained by well trained nurses to ensure safety and minimize side 
effects.  
2.1.5. Data management  
Data were collected on standardized proformas and dually entered, and validated 
into a database (ACCESS, Microsoft Corporation, Virginia, USA). Each study proforma 
was entered as a separate table linked in the database by the unique identifier assigned to 
each study subject. Personal identifiers were maintained separately in one main file in a 
password protected computer file and used only as necessary to match this information 
with the other databases. Only the investigators of the study had access to this 
information. To ensure quality control, questionnaires were checked at the end of each 
interview. On a monthly basis, a random sample of computerized records was compared 
with hard-copy case report forms for confirmation of consistency. Questionable values 
were flagged and cross-checked with paper records. When a discrepancy was noted, the 
nurse who was involved in entering the data was consulted to resolve the discrepancy, and 
if necessary, and if necessary and possible, the study participant was also contacted to 
resolve the issue. Data analysis was conducted using STATA version 8 (StataCorp, 
College Station, USA). 
 
2.1.6. Data analysis 
A priori α-level of 0.05 was set for all statistical comparisons unless otherwise 
specified.  Below is a description of the main study variables:  
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Dependent variables 
 
Birth weight: Birth weight was analyzed as a categorical variable. Newborns were 
classified as having normal birth weight (≥ 2500 g) or low birth weight (< 2500 g), 
regardless of gestational age.   
 
Maternal anemia: Hemoglobin concentration was also analyzed as a categorical variable. 
Women were classified as having anemia if they had hemoglobin concentration less than 
11g/L. Anemia was further classified into mild anemia (9-10.9 g/dL), moderate anemia (7-
8.9 g/dL) and severe anemia (<7g/dL) 12.  
 
Independent variable 
The main exposure variable, malaria infection during pregnancy, was defined as follows: 
 
1. The frequency of malaria infection was categorized according to the total number of 
episodes malaria experienced by the women between enrolment and delivery. We 
were expecting that very few women would have more than 3 episodes of malaria 
detected during pregnancy. Therefore, the frequency of malaria infection was analyzed 
as a disjoint indicator variable with 3 levels: 0 (the referent group representing women 
who had no malaria during pregnancy; 1 (women who had one episode of malaria 
detected); 2 (women who had 2 or more episodes of malaria detected between 
enrolment and delivery).  
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To assess if there was a dose-response relation in the risk of low birth weight or maternal 
anemia with increase in the number of episodes of malaria, the frequency of infections 
was coded using incremental coding, and women who had no infection during pregnancy 
were the reference category. The coding was as follows; 
Z1= 1 if ≥ 1 episode of malaria during pregnancy, 0 otherwise  
Z2=1, if ≥ 2 episodes of malaria during pregnancy, 0 otherwise 
 
 2.  The timing of malaria infection during pregnancy was classified as: 
(a) Malaria infection in the antenatal period only, and at delivery only. 
(b) Malaria infection in the first trimester (gestation age ≤ 12 weeks); infection in 
the second trimester (gestation age 13-28 weeks); and infection in the third 
trimester (gestation age 29 weeks-delivery). Because very few women attend 
antenatal clinics in the first trimester of pregnancy, we were expecting very few 
women to be in the first trimester category. Therefore women who had infection in 
the first trimester of pregnancy were excluded from this analysis.  
 
For both definitions of timing of infection, women who had no malaria infection during 
pregnancy were the reference group.  
 
Other study variables 
Gravidity was included in the analysis as an effect measure modifier. The other 
variables; age, use of insecticide treated bed-net (ITNs), use of SP for IPT, body mass 
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index (BMI), use of anti-malarial drugs prior to enrolment into the study, and gestation 
age at enrolment into the study were treated as potential confounders.   
 
Univariate analyses 
Univariate analyses involved examination of the distribution of baseline socio-
demographic characteristics of the study participants. Descriptive statistics for continuous 
characteristics included frequencies, means, standard deviation and range.  The 
distribution of continuous variables was examined for presence of outliers, and to decide 
whether there was need for transformation, rescaling or recoding into categorical 
variables. Cut-off points were developed using information from previous literature, 
critical percentiles or based on the distribution of data. The distribution of categorical data 
was described using frequencies and percentages. Some of the nominal variables with 
more than two categories were collapsed to a smaller number of categories if there were 
small numbers in some categories.  
 
Bivariate analyses 
Bivariate analyses compared baseline socio-demographic characteristics across the 
different exposure groups. Normally distributed continuous variables were compared 
using analysis of variance, and non-normally distributed continuous variables were 
compared using the Kruskal-Wallis tests. Differences in proportions for categorical 
variables were compared using the Chi-square test. Tabular analyses were also used to 
measure the association between categorical covariates and the exposure and outcome 
variables. For continuous variables, the assumption of linearity was assessed by creating 
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categories based on previous literature, using critical percentiles or based on the 
distribution of the data, and assessing a plot of the log odds of the outcomes in the created 
categories for linearity. For ordinal variables, linearity of the log odds of the outcome was 
assessed while maintaining the original categories if sufficient data was available for all 
categories or combining categories with insufficient data. When the assumption of 
linearity was violated, continuous and ordinal variables were converted into indicator 
variables.  
 
Assessment of effect measure modification 
The presence of effect measure modification was assessed using both tabular and 
regression analyses. In tabular analyses, effect estimates were computed for each stratum 
of the covariate. The Breslow Day test for homogeneity was used to compare the strata 
estimates. An a priori significance level of 0.15 was chosen, because the test for 
homogeneity has low power. Effect measure modification was also considered present if 
the effects in the stratum were different in relation to the null. Further evaluation of effect 
measure modification using regression analysis consisted of creating an interaction term 
between the main exposure variable and the potential effect measure modifier. This model 
was compared to one without the interaction term using the Likelihood ratio test. Effect 
measure modification was considered present if the Wald test p-value for the interaction 
term was less than 0.05. If effect measure modification was present, separate estimates 
were reported for each strata of the effect measure modifier.  
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Assessment of confounding 
The directed acyclic graph (DAG) was used to identify potential confounders of 
the association between malaria and LBW or anemia 13. Using the DAG criteria, a 
variable was considered a potential confounder if it was associated with the exposure and 
the outcome, but the variable was not an effect of the exposure or outcome, and there was 
an unblocked backdoor pathway from the exposure to the outcome. A backward 
elimination strategy was used to make select the best model that explained the association 
between exposure to malaria during pregnancy and low birth weight or maternal anemia. 
Confounding was assessed using the change in estimate criteria. The absolute change in 
estimate of at least 0.10 comparing the difference in the log odds of the crude estimate 
(full model) and the adjusted estimate (reduced model) was considered to indicate the 
presence of confounding by that variable. The full model, containing all the potential 
confounders was compared with models without each of the covariates. Variables that 
caused the least change in estimate were dropped subsequently until all variables left in 
the model caused a change in estimate of at least 0.10. If there was effect measure 
modification, the change in estimate was assessed for the individual stratum specific 
estimates in the full model and corresponding stratum specific estimates in the reduced 
model. The following variables were included as potential confounders:  ITNs use 
(yes/no); use of SP (none, 1 dose, 2 doses and 3 doses); use of anti-malarials prior to 
enrolment (yes/no); and gestation age at enrolment (second/third trimester). Maternal age 
which was continuous in the original dataset was converted into a binary variable, 
dichotomized at the age of 20 years, after assessing for linearity. Body mass index was 
entered as continuous in the model.  
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Multivariate analyses 
 
1. Malaria and low birth weight  
Multivariate analysis of the association between frequency and timing of P. 
falciparum infection during pregnancy and LBW or maternal anemia was performed using 
binomial regression 14. The full multivariate model included the outcome, main exposure 
variable, and all variables that were identified as confounders. Analyses were stratified by 
the number of follow-up visits. Gravidity was considered an effect measure modifier 
based on previous studies that have consistently found a difference in the effect of malaria 
on LBW and maternal anemia according to parity 15 . Therefore, effect estimates were 
reported separately for primigravidae (PG), and women of other parities (MG). The beta 
coefficients for the model were estimated using the Maximum likelihood method.  
 
The equation for the full model was as below: 
 
P (Y1=1|X1) = exp (β0 + β1X1 + β2X2 +……….+βkXk) 
 
Where Y is the dependent variable (low birth weight, maternal anemia) 
X1 is vector representing the independent variables (exposure to malaria and the 
propensity score) 
β represents the parameters estimating the effect of covariates in the model 
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We used the Cox proportional hazards model and the Poisson regression model to 
confirm the estimates obtained from the binomial regression model. We assigned a 
constant risk period to every woman in the study so that the hazard rate ratio estimated by 
Cox regression and rate estimated by the Poisson regression model would equal the 
prevalence ratio 16,17.  A robust variance estimator was included in the Cox proportional 
hazards model and the Poisson model for correction of the standard errors 18. The 
goodness-of-fit of the final model was also assessed using the Deviance test and 
examination of the distribution of standardized Pearson residuals for covariate patterns 
that were outliers.  
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2.2. Specific Aim II 
 
To assess the efficacy of azithromycin or artesunate combined with SP compared 
with SP monotherapy as treatment for malaria in pregnant women 
 
2.2.1. Rationale 
Currently SP is the drug of choice for IPT and treatment of malaria in pregnant 
women in Malawi and other countries in sub-Saharan Africa 19. With the emergence of 
resistance, the efficacy of SP is decreasing. This has raised concerns about its 
effectiveness in reducing malaria-related adverse events during pregnancy. There are 
insufficient safety data on the newer anti-malarial drugs and, therefore, a need to evaluate 
new anti-malarial drugs that could be used for prevention and treatment in pregnant 
women. One of the strategies being advocated to delay the development of drug resistance 
to anti-malarial drugs is the use of artemisinin-based combination therapy. Artemisinin 
derivatives are highly efficacious, rapidly active, and have action against a broader range 
of parasite developmental stages 20. Artesunate, one of the artemisinin derivatives has 
been used for treatment of malaria in malaria in combination with other drugs 21-23. 
However, due to the small number of women recruited into these studies, there is still 
need for more studies to assess its safety during pregnancy before it can be recommended 
for routine use. Azithromycin, a macrolide antibiotic, has anti-malarial activity 24,25and 
has been used widely in pregnant women to control sexually transmitted infection (STIs) 
such as gonorrhea and Chlamydia with a good safety profile 26 However there have been 
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no studies that have assessed its efficacy in treating and preventing malaria in pregnant 
women.  
 
2.2.2. Objectives 
The primary objective of the study was: 
1. To compare the recrudescence rates of malaria following SP monotherapy, SP-
artesunate and SP-azithromycin 
 
The secondary objectives of the study were:  
1. To compare the parasite clearance times of SP monotherapy, SP-artesunate, and SP- 
     azithromycin  
2. To examine the tolerability of SP-artesunate and SP-azithromycin. 
3. To examine the effect of SP-artesunate and SP-azithromycin on birth outcomes,  
    maternal parasitemia and hemoglobin concentration. 
 
2.2.3. Primary hypothesis 
Hypothesis addressed include:  
1. Treatment with SP-azithromycin and SP-artesunate results in a few recrudescence 
rates compared with SP monotherapy. 
2. Parasite clearance time is faster for SP-azithromycin and SP-artesunate compared 
with SP monotherapy 
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3. SP-azithromycin and SP-artesunate administration during pregnancy does not 
cause any severe maternal and pregnancy outcomes 
4. SP-azithromycin and SP-artesunate reduce the risk of low birth weight, maternal 
parasitemia and anemia   
 
2.2.4. Study design and methods 
 
Study setting 
The study setting was the same as already described for Specific Aim 1 
 
Study Population 
All pregnant women presenting at the two health centers for antenatal care were 
considered eligible for the study if they had peripheral parasitemia, were 15 to 49 years 
old, the fetal gestation age was between 14 and 26 weeks, the mother had felt fetal 
movements and if the women were available for follow-up during the entire period of the 
study.  Women were excluded from the study if they had a history of chronic diseases 
such as tuberculosis, diabetes, kidney and/or liver disease, multiple gestations, a mental 
disorder that could have affected their comprehension of the study or success to follow-
up, known allergies to drugs containing sulfonamides, macrolides or pyrimethamine, 
pregnancy complications at enrollment, and received anti-malarial drugs within 28 days 
before enrollment. A total of 141 women were recruited over a period of 8 months from 
September 2003 to May 2004.    
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Study procedures 
 Informed consent was obtained prior to enrollment into the study. Each woman 
was assigned a unique identification number and an identifying sticker was placed on their 
antenatal cards. Detailed contact information was obtained to be used at a later date to 
trace subjects, if they did not return for follow-up visits. Demographic information, past 
medical and obstetric history was obtained using a standardized questionnaire through an 
interview conducted by trained study nurses. The women also received routine antenatal 
assessment which included height, weight, temperature and blood pressure measurements 
and abdominal examination. Study nurses also investigated for the presence of high risk 
factors of the pregnancy. All the women enrolled into the study had the option to receive 
HIV counseling and testing.  The counseling was done by trained counselors who were 
fluent in the local language, Chichewa. A venous blood sample was obtained for 
measurement of maternal hemoglobin concentration, preparation of thick films, and 
syphilis testing.    
 
Subjects were randomly assigned to 3 treatment arms using computer generated 
random numbers that were grouped into blocks of 4-10. The three treatment arms 
consisted of: (1) SP (3 tablets) only; (2) SP (3 tablets) plus azithromycin 1g/day for 2 days 
and (3) SP (3 tablets) plus artesunate 200 mg/day for 3 days. Administration of the study 
drug was under direct observation by the study nurse. If the medication was vomited 
within 30 minutes of ingestion, another similar dose was administered. Women were 
asked to remain at the health center for at least an hour after the administration of drugs. 
Women who lived far away were asked to stay at the health center for 2 nights or were 
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visited by the study nurse in their home village. The women were given 200 mg of ferrous 
sulfate and 0.25 mg of folic acid for daily administration throughout pregnancy as part of 
the Malawi government policy. They were also given insecticide-treated bed-nets (ITNs) 
with instructions on how to use them.  
 
Follow-up 
Each woman received two doses of the assigned treatment and these were given at 
least 4 weeks apart. Thick films were examined on days 1,2,3,7 and 14 after receiving the 
assigned treatment.  Body temperature was recorded by the study nurses every 6 hours 
until it became normal (<37.5 0C). Women with peripheral parasitemia between day 7 and 
28 after administration of the first or the second dose of study drug were treated with 
quinine 600 mg, 3 times a day for 5 days as per Malawi government policy. At all the 
visits, blood samples (50 μl spots, 4 per sample) were spotted onto filter paper, air dried 
and stored in sealed plastic bags with dessicant for molecular analysis. The women were 
followed until delivery and were asked not to self-administer anti-malarial drugs. Instead 
they were asked to return to the health centers for evaluation any time they experienced 
symptoms of malaria, were febrile and for any other reason between scheduled visits. At 
each of the subsequent visits, they received routine antenatal care, and a standardized 
interview was conducted to obtain information on malarial illnesses, use of anti-malarial 
drugs and potential side effects of the study drugs. Thick blood films were also prepared.  
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Delivery 
The community TBAs and nurses at the QECH labor and delivery wards were 
enlisted to cooperate with this study. They were trained to obtain the requisite samples and 
information. All HIV-positive women were given nevirapine (Roxane Laboratories, 
Columbus, Ohio, USA) at the onset of active labor according to the HIVNET 012 protocol 
27 which was adopted by the Government of Malawi to prevent mother-to-child 
transmission (MTCT) of HIV. Newborns delivered at the health centers or QECH were 
weighed using a digital scale, and gestational age was assessed using the Ballard score 
within 24 hours of delivery by trained study nurses 28. Head and arm circumference and 
body length were measured using a tape measure. The newborns were also examined for 
the presence of congenital anomalies.  
 
Full thickness biopsies from a healthy paracentric area of the placenta were 
collected in 10% neutral buffered formalin for preparation of histology slides. A blood 
sample was obtained from a peripheral vein, the placenta and umbilical cord to prepare 
thick films, blood spots on a filter paper and to estimate maternal hemoglobin 
concentration. The filter papers were air-dried and stored in plastic Ziploc bags with 
dessicant for molecular assays. If a TBA was present for women delivering at home, birth 
weight was measured using color-coded scales that indicated green if the baby weighed 
more than 2500 grams and red if the baby weighed less than 2500 grams.  Peripheral, 
placental and cord thick blood films were prepared and forwarded to the health centers 
through community health workers. 
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Infant follow-up 
The women and their babies returned to the health centers at 1 and 4 weeks after 
delivery and their general health status was assessed. An attempt was made to determine 
the cause of any neonatal death by questioning the mother about premortal symptoms 
using an unstructured questionnaire.  Additional follow up visits were at 1, 3, 6 and 12 
months after delivery when the children were seen at the under five clinics. Health 
Surveillance Assistants (HSAs) tracked women and children who did not return and 
encouraged them to attend the clinics. 
 
Monitoring of adverse events 
All adverse events were followed closely by the study staff. Symptoms present at 
baseline were considered to be attributable to malaria. All patients requiring 
hospitalization were monitored at the health centers or were referred to QECH and visited 
daily in order to document progression/resolution of the adverse event and to provide any 
clinical services deemed necessary. Some of the clinical events considered serious were 
seizures, coma, diabetic ketoacidosis, diffuse petechiae and disseminated intravascular 
coagulation. Less serious adverse events were monitored at the health centers with 
outpatient management as deemed appropriate by the study physician. Treatment was 
discontinued if there were serious adverse events and these were reported to the 
institutional review boards (IRBs) of the University of Malawi, College of Medicine and 
the University of North Carolina within 48 hours. A Data Safety Management Committee 
(DSMB) was put in place to review data if there was an occurrence of serious adverse 
events from azithromycin or artesunate patients. 
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Laboratory Procedures 
 
Malaria diagnosis 
The diagnosis of malaria was the same as that described for specific Aim 1 
 
Placental biopsies 
Fixed placental biopsies were wax embedded and 4μm thick sections were cut into 
slides. Histological slides were prepared by staining with Gurr’s modified Giemsa and/or 
Hematoxylin and Eosin 8. The slides were examined for the presence of P. falciparum 
infected erythrocytes, and hemozoin deposition in fibrin and monocytes. Using a 
systematic method, 500 intervillous blood cells were counted under oil immersion to 
determine the level of parasitemia. The slides were classified into: (1) parasites, no 
pigment in monocytes or fibrin, (2) parasites, pigment in monocytes ± fibrin, (3) parasites, 
pigment in fibrin, (4) no parasites, pigment only (past infection), and (5) no parasites or 
pigment (no infection) 8. Placental histology was examined by an experienced pathologist 
without prior knowledge of the blood film microscopy results, treatment group 
assignment, maternal characteristics or pregnancy outcomes.  
 
Distinguishing reinfection from recrudescence 
Molecular genotyping of the msp-1 gene using a heteroduplex tracking assay 
(HTA) was performed on paired samples of women who had more than one episode of 
malaria during follow-up to distinguish between recrudescence and reinfection. The msp-1 
gene is highly variable, and therefore allows the identification of different strains of 
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infection 29. The HTA used a radioactive labeled oligonucleotide, which when bound to 
similar sequences, migrated down a polyacrylamide gel electrophoresis at a speed 
determined by the shape of the DNA duplexes 30,31. A strain with a unique sequence was 
identified in samples based on the location of the band on a gel. Investigators were 
blinded of the treatment allocation when deciding the outcome of a subsequent episode of 
malaria. 
 
HIV diagnosis 
HIV test was performed simultaneously using two enzyme immunoassays (EIA), 
Determine HIV-1/2 Rapid Test (Abbott Laboratories, Illinois, USA) and Unigold Test 
(Trinity Biotech plc, Dublin, Ireland) according to the manufacturers’ instructions. If these 
tests produced discordant results, a third assay, the Hemastrip Rapid Test (ChemBio 
Diagnostic Systems) was used to resolve the discrepancy.   
 
Measurement of Hemoglobin Levels 
Measurement of hemoglobin concentration was the same as that described for specific 
Aim 1 
 
Human Subjects 
IRB approval for the proposed study was granted by the University of North 
Carolina and the College of Medicine, University of Malawi. To ensure privacy and 
confidentially, HIV pre- and post-test counseling was conducted in private settings by 
trained counselors. The administered dose of SP was according to the Malawi government 
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national guidelines, and the doses of azithromycin and artesunate were similar to those 
used in previous studies which reported no adverse events 26,32,33. All drugs were 
purchased in one batch and stored at a dry cool place, to maintain quality.   
 
2.2.5. Data Management 
Procedures for data management were the same as described for specific aim I.  
 
2.2.6. Data analysis 
A priori α-level of 0.05 was set for all statistical comparisons unless otherwise 
specified.  Below is a description of main study variables.  
 
Dependent Variables 
 
Recrudescence: The primary outcome of interest was time to recrudescence after 
treatment with the assigned study drug. Recurrent infections were classified as 
recrudescence if parasitemia was detected from day 7 after drug administration 34. 
Recurrent episodes detected between days 7 and 14 were classified as recrudescence 
without genotyping because they were assumed very unlikely to be a new infection. For 
recurrent episodes that were detected after day 14, we genotyped the msp-1 gene to 
distinguish between recrudescence and new infections. Recurrent episodes that were 
genotyped were classified as recrudescence if the recurrent episode contained all or a 
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subset of variants (at least one identical uncommon band with prevalence <10% or at least 
2 common bands with a prevalence >10%) that were present in the initial infection.  
 
Parasite clearance time: This was defined as the time, in days, from the beginning of 
anti-malarial treatment until parasites were no longer detectable in a peripheral thick 
blood film.  
 
Birth outcomes: Abortion was defined as delivery of a non-viable fetus before 28 weeks 
gestation. Stillbirth was defined as delivery of a dead fetus after 28 weeks of gestation. 
Death occurring within 28 days of delivery was classified as neonatal death.  Low birth 
weight was defined as weight less than 2500 g at delivery. 
 
Maternal anemia: Women were classified as being anemic if they had hemoglobin 
concentration less than 11g/dL 12.   
 
Independent variable 
Treatment groups: The main exposure of interest was the treatment group. Data analysis 
was performed using the intention to treat principle. None of the women crossed over 
from the original assigned group to another treatment group during the follow-up period.  
 
Other study variables 
Variables included in the analysis as potential effect measure modifiers or 
confounders were maternal age, gravidity, education and socio-economic status. Socio-
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economic status was evaluated using a number of questions which enquired about the type 
of job, roofing and wall material of the house, sanitary facilities, source of drinking water 
and possession of a car, radio, mattress or bicycle. Clinical characteristics included 
baseline parasite density, HIV-infection status and use of quinine after recrudescence.   
 
Univariate analysis 
Univariate analyses involved the examination of the distribution of baseline 
demographic and clinical characteristics of the women by treatment group. Descriptive 
statistics for continuous characteristics included frequencies, means, standard deviation 
and range. The distribution of continuous variables was examined to identify possible cut-
off points for multivariate analysis.  The presence of outliers was noted and cross-checked 
with raw data for inconsistencies. The distribution of categorical and ordinal data was 
described using frequencies and percentages. Some categorical variables with more than 
two levels were either dichotomized, or changed to indicator variables with more than two 
levels, if the assumption of linearity was violated.   
 
Survival analysis was used to determine the efficacy of SP-artesunate and SP-
azithromycin compared with SP monotherapy. Individuals had an event if they had an 
episode of malaria that was classified as recrudescence during the follow-up period. 
Individuals were censored if they were lost to follow-up or had no event at the end of 
follow-up (delivery). Individuals contributed to the time at risk from the time they had an 
episode of malaria until they had an event, or when censored. There was no difference in 
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the distribution of failure times in censored and non-censored individuals when compared 
conditional on outcome. Therefore it was concluded that censoring was non-informative.  
 
The mechanism of missingness of data was also investigated. Except for HIV 
status which had 37% of the data missing, none of the other baseline characteristics in the 
dataset had missing data. There was no difference in the failure times and recrudescence 
rates between women who had an HIV test and those who did not have an HIV test. Data 
was missing on outcomes [maternal parasitemia (28%), hemoglobin concentration (29%) 
and birth weight (16%)] because women had moved out of the study areas, were lost to 
follow-up, delivered outside the study area or blood samples were not collected during a 
home delivery. There was no significant difference in the baseline characteristic between 
women who were lost to follow-up and those not lost to follow-up. Therefore, we 
assumed that missingness was completely at random, and complete case analysis was 
performed.  
 
Bivariate analysis  
Kaplan-Meier survival curves were used to calculate the conditional survival 
probability for the independent predictors of treatment outcome. Comparison of the 
survival curves was performed using the Log-rank or the Wilcoxon test. The assumption 
of a constant proportion hazard over time for the independent predictors was assessed 
graphically using log (-log (S (t))) curves, and the Cox test by adding an interaction term 
between a predictor and time in a Cox proportional hazards model. If the time dependent 
covariates were significant, it indicated that the hazards were not proportional and the 
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assumption was relaxed by either stratifying by that variable or including a time 
interaction term in the model.  
 
Analysis of the secondary outcomes (the cumulative incidence proportion of 
abortions, still births, low birth weight, maternal anemia and adverse events) was 
performed using tabular analysis. Differences in the proportions of the outcomes across 
the treatment groups were compared using the Fischer exact methods.    
 
Multivariate analysis 
Multivariate analysis of the efficacy of SP-azithromycin and SP-Artesunate 
compared with SP monotherapy was performed using a conditional risk-set Cox 
proportional hazards model, an extension of the Cox model that was stratified by the 
number of treatment doses received 35.  Each individual had two data lines representing 
the two doses of the drug they received. The risk intervals for the model were defined 
using gap time. Follow-up time for the first data line for each subject was time from the 
first treatment to time of event, censoring or just before the second treatment. Follow-up 
period for the second data line represented the time from second treatment to the event, or 
censoring (delivery or loss to follow-up). The model assumed a different baseline hazard 
for each stratum, and therefore, was stratified by the number of treatment doses received. 
A robust variance estimator was included in the model to account for the correlation of 
data in each woman 18. The Efron estimation of the partial likelihood was used to account 
for ties.  
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A backward elimination strategy was used to select the best model that assessed 
the efficacy of SP-azithromycin and SP-artesunate compared with SP monotherapy. The 
multivariate model included the main exposure variable, potential confounders and effect 
measure modifiers. The presence of effect measure modification was assessed using the 
Likelihood-ratio test. This was done by comparing the full model containing all variables 
including an interaction term with a reduced model that did not contain the interaction 
term. The remaining covariates were assessed for confounding using the change in 
estimate criteria.  Although treatment allocation was randomized, we still adjusted for 
confounding to control for residual confounding. The absolute change in estimate of at 
least 0.10 comparing the difference in the log hazard ratio of the crude estimate (full 
model) and the adjusted estimate (reduced model) was considered to indicate the presence 
of confounding by a variable and it was retained in the full model. Variables with more 
than two levels were tested together as a chunk. The variable which caused the least 
change in estimate was the first to be removed from the full model followed consecutively 
by variables which caused the least estimate. Only variables that caused an absolute 
change in estimate of at least 0.10 were left in the final model.  
 
Goodness of fit of the model 
We examined the correlation between the Schoenfeld partial residuals of the final 
model and the rank order of failure time for goodness of fit of the model 36.  
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Sensitivity analysis 
Malawi is a high-transmission area with a diverse P. falciparum parasite 
population. We identified three msp-1 variants that were common, with prevalence rates 
between 11% and 16%.  These common variants would have been classified as 
recrudescence if they were detected in a recurrent episode, even if it were a new infection.   
We conducted sensitivity analysis to assess the impact that misclassification of recurrent 
infections that shared only a single common variant (prevalence >10%) with the initial 
infection would have had on the efficacy of the combination therapies. We used the 
prevalence of the common bands and the total number of variants in the recurrent episode 
to calculate the probability the recurrent episode was a recrudescence. For a recurrent 
episode with x variants and sharing a single variant of prevalence y with the initial 
infection, the binomial probability that this variant was found by chance in a recurrent 
infection was equal to 1-(1-y)x (and therefore the probability that it represented a failure 
=(1-y)x).  Using the calculated probabilities, we recalculated the hazard ratios by varying 
the probability of recrudescence from 0.10, when all infections that shared a single 
common band were classified as recrudescent to 0.8 were none of the infections that 
shared a single common band were considered recrudescence.  
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Abstract 
 
Background: In areas of endemic transmission, Plasmodium falciparum infection during 
pregnancy causes maternal anemia and low birth weight. However the effect frequency 
and timing of infection on the severity of these adverse effects is not known. This 
information would be important for developing prevention policies in pregnant women.   
 
Methods: We conducted a prospective observational study recruiting 2,462 pregnant 
women in Blantyre, Malawi. The presence of malaria was assessed by microscopy at 
scheduled visits during follow-up and delivery. Birth weight and maternal hemoglobin 
concentration were measured at delivery. The association between timing and frequency 
of malaria infection on the risk of low birth weight and maternal anemia was analyzed 
using a binomial regression model..   
 
Results: The prevalence of low birth weight increased with the number of malaria 
episodes: [Primigravidae: 1 episode (prevalence ratio [PR] =2.72; 95% C.I. 1.06-7.00), 
and 2 or more episodes (PR=3.16; 95% C.I. 1.11-9.04); Multigravidae: 1 episode (PR 
=1.26; 95% C.I. 0.51-3.11) and 2 or more episodes (PR=3.00; 95% C.I. 0.79-11.41)]. The 
prevalence of anemia also increased with the number of episodes of malaria: 
[Primigravidae: 1 episode (PR= 1.07; 95% C.I. 0.52-2.19) and 2 or more episodes (PR= 
1.57; 95% C.I. 0.70-3.54); Multigravidae: 1 episode (PR= 1.09; 95% C.I. 0.62-1.91) and 2 
or more episodes (PR= 1.53; 95% C.I. 0.54-4.30]. The prevalence of low birth weight was 
higher with infection in the second trimester (PR=2.97; 95% CI 1.60-5.53) than in the 
third trimester (PR=1.42; 95% CI 0.63-3.22). The prevalence of maternal anemia was 
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higher with infection in the third trimester (PR=1.44; 95% CI 0.90-2.29) compared with 
infection in the second trimester (PR=0.94; 95% CI 0.51-1.71).  
 
Conclusion: Timing and frequency of Plasmodium falciparum infection during pregnancy 
affect the risk of low birth weight and maternal anemia. There is need to increase 
coverage of prevention measures against malaria throughout pregnancy to reduce the risk 
of these complications.  
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Introduction 
Each year more than 50 million pregnant women become pregnant in malaria 
endemic areas 1. The complications of P. falciparum infection during pregnancy are 
dependent on transmission rates and the level of acquired immunity. Women in low 
transmission areas are at risk for severe disease with a potential for mortality 2,3. They are 
also at risk for severe pregnancy complications such as spontaneous abortions, still births 
and low birth weight (LBW). In high transmission areas, women have acquired partial 
immunity by the time they reach reproductive age 4,5. Consequently they are not at risk for 
severe disease, but are at an increased risk for developing anemia and delivering babies 
with LBW.  
 
The actual mechanisms on how P. falciparum infection during pregnancy causes 
LBW still remain unclear. Some factors that have been cited include maternal anemia 6, 
placental insufficiency caused by the thickening of the trophoblastic membrane7,8, 
elevated proinflammatory cytokine levels9,10, poor oxygen and glucose transfer from the 
parasitized erythrocytes and use of nutrients by macrophages sequestered in the 
placenta10. The etiology of maternal anemia caused by P. falciparum infection during 
pregnancy is also multi-factorial. It is mediated through hemolysis of both infected and 
uninfected erythrocytes 11-13, phagocytosis of erythrocytes by macrophages, and poor bone 
marrow response14. However, the contribution of each of these factors to the development 
of maternal anemia has not been clearly elucidated. 
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Most studies have examined the association between P. falciparum infection and 
the adverse outcomes using placental histology to describe the evolution of infection 
during pregnancy4,7,15-21. However, the assessment of malaria at a single time point may 
result in misclassification. Other studies have limited recruitment to primigravidae 22. 
Although P. falciparum infection in multigravidae is not infrequent, it still poses a 
significant risk for severe anemia and LBW. To our knowledge, no studies have 
investigated the effect of frequency of P. falciparum infection during pregnancy on the 
risk of low birth weight and maternal anemia. We therefore conducted a prospective study 
following women during pregnancy to investigate the impact of timing and frequency of 
P. falciparum malaria on the risk of LBW and maternal anemia. This information would 
aid policy makers to identify the crucial time point when intermittent presumptive therapy 
(IPT) would be most effective in preventing malaria during pregnancy and its 
complications.  
Methods 
 
Study site 
The study was conducted at Mpemba and Madziabango health centers in Blantyre 
District, in the southern region of Malawi. Blantyre district covers 2012 km2 with a 
population of approximately 950,000 people 23. Malaria transmission is perennial but 
peaks during the rainy season (November to March). P. falciparum causes over 90% of all 
malaria infections. The two health-centers have maternity beds for delivery of low risk 
pregnancies, a malaria microscopy laboratory with a trained medical technologist, 4 full-
time and 9 part-time nurses. There are 18 traditional birth attendants (TBAs) that take care 
of births that occur in the community. Women with high risk pregnancies are referred to 
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Queen Elizabeth Central Hospital (QECH), a tertiary hospital located approximately 10 
km away from the health centers for management and delivery. 
 
Study population and recruitment 
All pregnant women attending routine antenatal care at the two health facilities 
were invited to participate in the study. A total of 2,462 women were recruited over a 
period of 15 months, between April 2002 and July 2003. Signed or witnessed verbal 
consent was sought for participation in the study before enrollment. A standardized 
questionnaire was used to obtain information on demographics, past obstetric history, 
malaria symptoms and factors associated with malaria prevention measures such as use of 
insecticide-treated bed nets (ITNs) and anti-malarial drugs in pregnancy. Study 
participants were given study numbers to retain until delivery for easy identification. 
Detailed contact information was obtained to aid in follow-up. The women received 
routine antenatal assessment which included height, weight, temperature and blood 
pressure measurements, and abdominal examination. A sample of venous blood was 
collected for hemoglobin concentration estimation and examination of thick blood films. 
The women were given a dose of sulfadoxine-pyrimethamine (SP) as intermittent 
preventive therapy (IPT) under direct observation by the antenatal clinic personnel. 
Antenatal records were checked to ensure that SP was not given at intervals less than one 
month.  
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Follow-up 
The follow-up visits were scheduled according to the normal antenatal routine 
care. Depending on the gestation age at enrollment, women were seen at the following 
gestational ages: 12 weeks, 26weeks, 32 weeks and 36-38 weeks age and at delivery. At 
these visits, women received routine antenatal care and a standardized interview was 
conducted to obtain information on malarial illnesses and use of anti-malarial drugs. A 
peripheral blood sample was obtained for examination of thick films and the women were 
given a second dose of SP according to the Malawi national policy schedule. The women 
were followed until delivery and were encouraged to deliver at the health centers.  
 
Delivery  
Blood samples were obtained soon after delivery for measurement of maternal 
hemoglobin concentration and examination of peripheral, placental and cord thick films. 
Newborns were weighed within 24 hours of delivery using a digital scale to the nearest 
gram. A system was set up such that community nurses and TBAs were able to identify 
women enrolled in the study, who delivered at home. TBAs were trained to prepare 
peripheral, placental and cord thick films from women who delivered in the community 
and forward them to the clinics through community health workers. Newborns delivered 
in the community were weighed using color coded scales that indicated green if the 
newborn weighed more than 2,500 grams and red if the newborn weighed less than 2,500 
grams.  
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Laboratory methods 
Malaria diagnosis was performed using microscopy of Giemsa stained thick blood 
films. Slides were examined under a microscope using a magnification of 100x oil 
immersion objective to detect and quantify parasitemia. Parasite densities were estimated 
using an assumed leukocyte count of 6,000 leukocytes/μl of blood. A thick film was 
considered negative if no parasites were detected after examining 100 microscopic fields 
each containing approximately 20 white blood cells. All thick films were read by two 
skilled microscopists and any discrepancies (positive versus negative or more than 25% 
difference in parasite density) were solved by repeating the readings. Hemoglobin 
concentration was determined using a HemoCueÒ machine (HemoCue Incorporated, 
Angelholm, Sweden).  
 
Outcome definitions 
Newborns were classified as having normal birth weight (≥ 2,500 g) or LBW (< 
2,500 g), regardless of gestational age.  Women were defined as having anemia if they had 
hemoglobin concentration less than 11g/dL 24.  
Ethical approval and consent
This study was approved by the College of Medicine Research Committee 
(University of Malawi, Blantyre, Malawi) and the Institutional Review Boards of the 
University of North Carolina (Chapel Hill, NC).  
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Statistical Analysis 
Data analysis was performed using STATA version 8.0 software (StataCorp, 
College Station, Texas, USA). Comparison of the baseline demographic characteristics 
was performed using the chi-square test for categorical data, analysis of variance for 
normally distributed, and the Kruskal-Wallis tests for non-normally distributed continuous 
variables. The frequency of malaria infection was classified according to the number of 
episodes detected during pregnancy. The timing of malaria infection during pregnancy 
was defined in two ways. Firstly, timing of infection during pregnancy was defined as: (1) 
parasitemia in the antenatal period only and (2) parasitemia at delivery only. Secondly, 
timing of infection was defined as: (1) parasitemia in the second trimester (gestation age 
13 to 28 weeks), and (2) parasitemia in the third trimester (gestation age 29 weeks to 
term). Multivariate analyses were performed using a binomial regression model to 
estimate the association between timing and frequency of P. falciparum infection during 
pregnancy and LBW or maternal anemia. We stratified the analysis by the total number of 
visits during follow-up. Gravidity was considered an effect measure, and estimates were 
reported separately for primigravidae (PG) and multigravidae (MG). Variables were 
considered confounders if there was an absolute change in estimate of 0.10 after 
comparing the full model and the reduced model without the variable. A backward 
elimination strategy was used to identify the best model. Covariates that were considered 
as potential confounders included maternal age, body mass index (BMI), use of ITNs, SP 
use during pregnancy, gestation age at enrolment, taking anti-malarial drugs and prior to 
enrolment into the study. All p-values are two-sided, and confidence intervals (CIs) were 
calculated at the 95% level. Statistical significance was set at p≤ 0.05. 
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Results 
Study Population 
Of the 2,462 women enrolled into the study, birth weight was recorded for 1,548 
newborns and information on hemoglobin concentration at delivery was available for 
1,253 women. Data was missing for birth weight and maternal hemoglobin concentration 
because women had moved or delivered outside the study area, or failed to return for 
follow-up and the study team were unable to locate their houses. There were no significant 
differences in most of the baseline characteristics in the women who were included in the 
analysis and those lost to follow, except for reported ITNs ownership and use of IPT SP 
(Table 3.1). Analysis was restricted to women who were enrolled at their first antenatal 
visit with information on outcome [birth weight (n=1,162), and maternal hemoglobin 
concentration at delivery (n=973)]. The total number of visits by the women enrolled into 
the study was as follows: 1 visit [9.6%, (n=190)], 2 visits [44.0%, (n=870)], 3 visits 
[40.3% (n=798)] and 4 visits [6.1% (n=121)]. The characteristics of women enrolled into 
the study are shown in Table 3.2. The mean maternal age was 24 years, and the mean 
gestational age at enrollment was 22 weeks, and 12.7% of the women reported owning 
ITNs. 
 
Malaria 
The prevalence of parasitemia at enrolment was 18.6%, higher in PG compared 
with MG, (38.2% vs. 12.2%; prevalence ratio [PR] = 3.13; 95% confidence interval (CI), 
2.60-3.75). The prevalence of parasitemia throughout pregnancy was also higher in PG 
compared with MG (49.6% versus 20.6%; PR= 2.40, 95% CI 2.09-2.76). More women 
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had parasitemia in the antenatal period than at delivery irrespective of gravidity (20.5% 
versus 4.6%, p<0.0001). The frequency and timing of infection during pregnancy 
according to gravidity are shown in Table 3.3. After adjusting for other baseline 
characteristics, parasitemia was more common among PG compared with MG (PR=2.35, 
95% CI 1.93-2.86). Women who were enrolled in the third trimester of pregnancy had less 
parasitemia compared with women enrolled in the second trimester (PR=0.77, 95% CI 
0.62-0.96). The association between P. falciparum infection during pregnancy and other 
baseline characteristics of the study population are shown in Table 3.4.   
 
Low birth weight 
The mean birth weight was 3018.2 g (standard deviation (SD), 482.3 g), and the 
prevalence of LBW was 9.3%. Gravidity, maternal age and bed net use were significantly 
associated with low birth weight in bivariate analysis, p<0.05. After adjustment for other 
baseline characteristics, only gravidity was still significantly associated with the risk of 
LBW. The proportion of LBW deliveries was more common among PG than MG (17.5% 
vs. 6.8%; PR=2.24; 95% CI, 1.34 -3.75) (Table 3.4).    
 
Maternal hemoglobin 
The prevalence of mild and moderate-to-severe anemia at enrollment was 53.1% 
and 14.8%, respectively. The prevalence of mild and moderate-to-severe anemia at 
delivery was 19.4% and 3.2% respectively. After adjusting for other baseline 
characteristics, the prevalence of anemia at delivery was higher in women who had 
malaria during pregnancy compared with those who did not have infection (PR=1.28; 
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95% CI 0.98-1.66). Women who did not own ITNs were more likely to have anemia at 
delivery than women who owned ITNs (PR=1.24; 95% CI 0.87-1.77). Other factors 
associated with anemia during pregnancy are shown in Table 3.5.  
 
Effect of frequency of malaria infection on low birth weight and maternal anemia 
 The prevalence of LBW increased with the number of episodes experienced 
during pregnancy. Compared with PG who had no malaria during pregnancy, the 
prevalence of LBW for PG with one episode of malaria was (PR=2.72; 95% 1.06-7.00), 
and 2 or more episodes was (PR=3.16; 95% 1.11-9.04). Similarly in MG, the prevalence 
of LBW increased with the number of episodes of malaria [1 episode: (PR 1.26, 95% CI 
0.51-3.11), and 2 or more episodes: (PR 3.00, 95% CI 0.79-11.41)]. The prevalence of 
maternal anemia also increased with the number of episodes of infection both in PG and 
MG. Compared with PG who had no malaria during pregnancy, the prevalence of anemia 
with 1 episode of malaria was (PR=1.07, 95% CI 0.52-2.19), and 2 or more episodes was 
(PR=1.57, 95% CI 0.70-3.54). The prevalence of maternal anemia comparing MG who 
had no infection with MG who had 1 episode of malaria was (PR=1.09, 95% CI 0.62-
1.91), and 2 or more episodes was (PR=1.53, 95% CI 0.54-4.30), (Table 3.6). 
 
The effect of timing of malaria infection on low birth weight and maternal anemia 
The prevalence of LBW and maternal anemia varied with the time of infection 
during pregnancy. Because of small numbers, estimates were combined for PG and MG. 
Compared with women who had no infection during pregnancy, the prevalence of LBW 
was higher in women who had infection in the antenatal period (PR=2.24; 95% CI 1.21-
4.13) than in women who had infection at delivery (PR=2.13; 95% CI 0.90-5.01). In the 
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antenatal period, the prevalence of LBW was higher for women who had infection in the 
second trimester (PR=2.97; 95% CI 1.60-5.53) compared with infection in the third 
trimester (PR=1.42; 95% CI 0.63-3.22). The prevalence of maternal anemia was higher in 
women who had infection at delivery (PR=1.52; 95% CI 0.83-2.78) compared with 
infection in the antenatal period (PR=1.03; 95% CI 0.63-1.68). When timing was 
classified using trimester of pregnancy, the prevalence of maternal anemia was also higher 
in women with infection in the third trimester (PR=1.44; 95% CI 0.90-2.29) compared 
with infection in the second trimester (PR=0.94; 95% CI 0.51-1.71), (Table 3.7).  
Discussion 
We investigated the association between the frequency and timing of P. 
falciparum infection during pregnancy on the risk of low birth weight and maternal 
anemia in a large sample of pregnant women in Malawi. We found that the prevalence of 
low birth weight and maternal anemia increased with the number of episodes of infection 
experienced during pregnancy, irrespective of gravidity. Timing of infection also affected 
the risk of LBW and maternal anemia. Infection detected early in pregnancy (antenatal 
period or second trimester) increased the prevalence of LBW more than infection detected 
in late in pregnancy (third trimester or at delivery). By contrast, the prevalence of 
maternal anemia was higher with infection late in pregnancy compared with infection 
early in pregnancy.  
 
 P. falciparum infection during pregnancy is characterized by the 
sequestration of infected erythrocytes in the maternal placental vascular space 25. Studies 
have shown that this sequestration causes an infiltration of inflammatory cells and 
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elevation of cytokine levels in the infected placentae 9,10,26. It has been suggested that this 
inflammatory response reduces the materno-fetal exchange of nutrients through poor 
oxygen and glucose transfer by parasitized erythrocytes, use of nutrients by the growing 
parasites and placenta mechanical blockage due to thickening of the basement membrane 
7-10, leading to growth restriction in the fetus. We found that the risk of low birth weight 
increased with the number of episodes experienced during pregnancy. This suggests that 
the damage caused in the placenta by the sequestration of malaria parasites is reversible. If 
the damage had been permanent, the risk for low birth weight would not have changed 
irrespective of the number of episodes experienced during pregnancy. Previous studies 
have found that women with infections early in pregnancy did not show histological 
differences seen in infected placentae at delivery8,27,28, suggesting that the placenta is able 
to recover from acute infections. We also found that the timing of infection during 
pregnancy affected the risk of low birth weight. The prevalence of low birth weight was 
higher in women who had infection early in pregnancy than infection detected late in 
pregnancy. Maximum fetal growth rate occurs between 20 and 28 week gestation, this 
would explain why infection in the second trimester increased the risk of low birth weight 
more than infection in the third trimester.  
 
We also found that the risk of maternal anemia increased with the number of 
episodes of infection experienced during pregnancy both in primigravidae and 
multigravidae. Compared with women who had no infection during pregnancy, the mean 
hemoglobin concentration was 0.2 g/dL lower for women who had 1 episode, and 0.8 
g/dL lower for women with 2 or more episodes of malaria during pregnancy. Women who 
had infection in the third trimester of pregnancy or at delivery had a higher risk of 
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maternal anemia than women who had infection in the second trimester or in the antenatal 
period.  Malaria infection during pregnancy causes anemia through hemolysis of infected 
and uninfected erythrocytes, and poor bone marrow response 11,12,14. The women in our 
study were given SP for IPT and ferrous sulphate supplementation during follow-up, 
which could have raised the hemoglobin concentration after infection early in pregnancy, 
reducing the risk of anemia at delivery.  
 
Our findings are important for developing preventive policies in pregnant women. 
Most malaria-endemic areas have limited resources and most women do not receive the 
recommended two doses of SP during pregnancy. Access is limited by many factors 
including low providers' awareness of the regimen, poor health-seeking behavior of 
pregnant women who tend not to receive antenatal care and poor availability of drugs. 
Additionally, most women in malaria-endemic areas present late in pregnancy for 
antenatal care 29,30. Administration of sulfadoxine-pyrimethamine at this time could still 
reduce the prevalence of low birth weight. Although the prevalence of low birth weight 
and maternal anemia was higher in PG, the adverse effects were also seen in 
multigravidae, indicating the need to include MG in future studies and policies on 
prevention of malaria during pregnancy.  
 
 Our study had several limitations. We did not obtain information on HIV which is 
associated with malaria and its complications and this could have biased our results. There 
were very few women who presented during their first trimester of pregnancy. Other 
previous studies have also noted that women in rural areas of Malawi tend to seek health 
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care in the middle to late second trimester 29,30. Therefore, we were unable to investigate 
the impact of malaria infection during the first trimester of pregnancy. We had expected 
that many women would deliver at home and, therefore, recruited traditional birth 
attendants to help us collect data for home deliveries. Despite extensive attempts, loss to 
follow-up was a concern in this investigation and occurred in part because of the highly 
mobile nature of this peri-urban study population. There were no significant differences in 
the baseline characteristics of the women who were lost to follow-up and women included 
in the analysis. Most of the women who were lost to follow up had moved out of the study 
area and therefore it is impossible to determine whether the outcomes in these women 
would have been different from the women who remained and delivered in the study area. 
Despite these limitations, our study sample was community based, recruiting women who 
were using the government health centers, which are primarily used by the majority of 
population living in the study area. A recent survey conducted in Malawi found that more 
than 90% of pregnant women visit antenatal clinics at least once during pregnancy 31. 
Therefore, the study sample was most likely representative of the pregnant women 
population living in the rural areas of Malawi. 
 
In conclusion, the timing and frequency of P. falciparum infection during 
pregnancy have an effect on the risk of low birth weight and maternal anemia. The 
prevalence of both maternal anemia and LBW increased with the number of episodes of 
malaria experienced during pregnancy. The prevalence of LBW was higher with infection 
early in pregnancy whereas the risk of maternal anemia was higher with infection late in 
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pregnancy. There is need to improve access to intermittent preventive therapy and other 
preventive measures throughout pregnancy to reduce the risk of complications of malaria.   
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Table 3.1. Comparison of the baseline characteristics of women who were lost and 
not lost to follow-up  
 
Characteristic Women not lost to 
follow-up 
(n=1759) 
Women lost to 
follow-up 
(n=703) 
P-value 
 
 
 
Age [median, (IQR)], years 
 
22  (20-27) 
 
23 (20-27) 
 
0.74 
Gravidity (%)    
    Primigravidae 76.9 74.4 0.18 
    Multigravidae 23.4 25.7  
Bed-net usage (%) 14.6 7.5 0.001 
Gestation age [median, (IQR)], 
weeks 
24 (22-28) 24 (22-27) 0.54 
Body mass index [mean, (SD)], 
kg/m2
21.6 (2.2) 21.6 (2.5) 0.99 
Hemoglobin [mean, (SD)],g/dl 10.2 (1.5) 10.3 (1.4) 0.19 
Maternal anemia† (%) 66.8 64.8 0.35 
Routine SP treatment ≥ 2 doses 
(%) 
67.8 70.1 <0.0001 
 
†- Anemia defined as as hemoglobin concentration less than 11g/dL ; IQR- interquartile 
range ; SD- standard deviation ; SP-sulfadoxine-pyrimethamine 
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Table 3. 2. The baseline characteristics of the women enrolled into the study with 
and without malaria during pregnancy 
 
Characteristic All women 
(n=1869) 
Malaria 
positive§ 
(n=515) 
Malaria 
negative¶
(n=1354) 
P-value 
 
 
 
Age [median, (IQR)], years 
 
23 (20-27) 
 
21 (19-25) 
 
23 (20-28) 
 
<0.0001 
Gravidity (%)     
    Primigravidae 23.9 43.0 16.7 <0.0001 
    Multigravidae 76.1 57.0 83.4  
Bed-net usage (%) 12.7 11.3 13.2 NS 
Gestation age [median, 
(IQR)], weeks 
24 (22-26) 24 (20-26) 24 (22-27) NS 
Body mass index [mean, 
(SD)], kg/m2
21.6 (2.4) 21.3 (2.4) 21.7 (2.3) 0.01 
Hemoglobin [mean, 
(SD)],g/dl 
10.1 (1.4) 9.9 (1.4) 10.2 (1.3) <0.0001 
Maternal anemia† (%) 67.9 73.6 65.7 <0.00001 
Routine SP treatment ≥ 2 
doses (%) 
63.6 70.5 60.8 <0.0001 
 
IQR- Interquartile range; SD-standard deviation; SP-sulfadoxine-pyrimethamine 
§ Women who had at least one episode of P. falciparum infection detected during 
pregnancy 
¶ Women who had no P. falciparum infection detected during pregnancy 
† Anemia was defined as hemoglobin concentration less than 11g/dL
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Table 3.3. The frequency and timing of P. falciparum infection during pregnancy by 
gravidity 
 
 Primigravidae 
(n=475) 
Multigravidae 
(n=1482) 
P-value 
 
 
Frequency of infection    
No episodes 223 (50.5) 1116 (79.4)  
1 Episode 170 (38.5) 255 (18.1) <0.0001 
2 or more episodes 49 (11.1) 35 (2.5)  
    
Time of infection§    
Antenatal period only 149 (37.0) 215 (15.5) <0.0001 
Delivery only 31 (7.7) 53 (3.8)  
    
Time of infection†    
Second trimester 120 (30.0) 133 (9.7) <0.0001 
Third trimester 57 (14.3) 128 (9.3)  
 
§Time of infection during pregnancy was classified as having parasitemia in the antenatal period only, or at 
delivery only 
† Time of infection during pregnancy was classified according to trimester of pregnancy: second trimester 
(gestation age 13 to 28 weeks), and third trimester (gestation age 28 weeks to term) 
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Table 3.4. Characteristics associated with P. falciparum infection during pregnancy 
Characteristic N (%)† Crude PR  
(95% CI) 
Adjusted PR  
(95% CI) 
 
Age  
    
     ≥ 20 years 1424 23.2 1.00 1.00 
     Less than 20 years 425 42.1 1.92 (1.63-2,26) 0.97 (0.79-1.18) 
Gravidity     
     Multigravidae 1406 20.6 1.00 1.00 
     Primigravidae 442 49.6 2.58 (2.21-3.02) 2.35 (1.93-2.86) 
Bed-net use     
     Yes 233 24.4 1.00 1.00 
     No 1604 28.0 1.02 (0.98-1.06) 1.03 (0.80-1.33) 
Use of SP as IPT     
     1 dose 681  22.3 1.00 1.00 
     2 doses 975 28.9 1.30 (1.09-1.54) 0.84 (0.65-1.08) 
     3 doses 213 38.0 1.70 (1.37-2.13) 0.90 (0.58-1.4133) 
Body mass index  (kg/m2)     
     <18.5 130 36.1 1.00 1.00 
     18.5-24.9 1544 26.8 0.74 (0.58-0.94) 0.84 (0.65-1.08) 
     ≥ 25 136 27.2 0.75 (0.53-1.08) 0.84 (0.58-1.21) 
Prior use of antimalarial drugs     
     Yes 94 26.6 1.00 1.00 
     No 1770 27.6 1.04 (0.73-1.47) 1.00 (0.71-1.42) 
Gestation at enrollment     
    Second trimester 1412 29.5 1.00 1.00 
    Third trimester 412 20.2 0.68 (0.55-0.84) 0.77 (0.62-0.96) 
Total number of visits during 
follow-up 
    
   2 visits 801 20.5 1.00 1.00 
    3 visits 767 33.3 1.62 (1.37-1.92) 1.78 (1.36-2.32) 
    4 visits 121 46.3 2.26 (1.79-2.86) 2.37 (1.51-3.71) 
N- Total number of women with information in the specified category; PR- Prevalence ratio; CI- 
Confidence interval; SP-sulfadoxine-pyrimethamine ; IPT-intermittent preventive therapy 
† Percentage of people with malaria; *Use of antimalarial drugs prior to enrolment into the study  
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Table 3.5. Characteristics associated with low birth weight 
 
Characteristic N (%)† Crude PR 
  (95% CI) 
Adjusted PR  
   (95% CI) 
 
Age  
    
     ≥ 20 years 870 7.5 1.00 1.00 
     Less than 20 years 283 14.8 1.70 (1.31-2.21) 1.05 (0.63-1.77) 
 
Gravidity     
     Multigravidae 851 6.8 1.00 1.00 
     Primigravidae 303 16.5 1.91 (1.52-2.41) 2.24 (1.34-3.75) 
 
Maternal anemia     
     No 269 7.1 1.00 1.00 
     Yes 827 10.0 1.09 (0.98-1.20) 1.11 (0.72-1.72) 
 
Bed-net use     
     Yes 174 5.2 1.00 1.00 
     No 969 10.1 1.09 (1.02-1.16) 1.93 (0.96-3.92) 
 
Use of SP as IPT     
     1 dose 449 10.2 1.00 1.00 
     2 doses 602 8.9 0.88 (0.60-1.27) 0.85 (0.58-1.25) 
     3 doses 111 7.2 0.70 (0.34-1.45) 0.70 (0.33-1.50) 
 
Body mass index  
(kg/m2) 
    
     <18.5 85 11.8 1.00 1.00 
     18.5-24.9 945 9.4 0.80 (0.43-1.48) 0.89 (0.47-1.68) 
     ≥ 25 90 5.6 0.47 (0.17-1.33) 0.55 (0.19-1.57) 
 
Gestation at enrolment     
     Second trimester 904 9.8 1.00 1.00 
     Third trimester 235 6.8 0.69 (0.41-1.15) 0.75 (0.43-1.30) 
 
Prior use of 
antimalarial drugs* 
    
     Yes 61  9.8  1.00 1.00 
     No 1097 9.3 0.95 (0.43-2.07) 0.87 (0.41-1.82) 
 
N- Total number of babies with birth weight information in the specified category; PR-Prevalence ratio; CI-
Confidence interval; SP-sulfadoxine-pyrimethamine ; IPT-intermittent preventive therapy 
†-percentage of babies with low birth weight; ‡ women who had anemia at delivery 
*-Use of antimalarial drugs prior to enrolment into the study 
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 Table 3.6. Characteristics associated with maternal anemia* at delivery 
 
Characteristic N (%)† Crude PR 
  (95% CI) 
Adjusted PR  
   (95% CI) 
 
Age  
    
     ≥ 20 years 729 21.8 1.00 1.00 
     Less than 20 years 239 25.5 1.17 (0.91-1.49) 1.04 (0.74-1.45) 
 
Parity     
     Multigravidae 713 21.3 1.00 1.00 
     Primigravidae 255 25.9 1.20 (0.94-1.52) 1.09 (0.78-1.53) 
 
Malaria during pregnancy     
     No 661 21.0 1.00 1.00 
     Yes 312 26.0 1.20 (0.98-1.47) 1.28 (0.98-1.66) 
 
SP use for IPT     
     1 dose 362 28.2 1.00 1.00 
     2 doses 518 18.2 0.64 (0.50-0.82) 0.62 (0.48-0.80) 
     3 doses 93 25.8 0.92 (0.63-1.34) 0.76 (0.49-1.16) 
 
Bed-net use     
     Yes 150 19.3 1.00 1.00 
     No 808 23.3 1.04 (0.97-1.10) 1.24 (0.87-1.77) 
 
Body mass index  (kg/m2)     
     <18.5 70 19.0 1.00 1.00 
     18.5-24.9 795 23.0 1.16 (0.71-1.88) 1.14 (0.70-1.86) 
     ≥ 25 72 22.2 1.11 (0.59-2.10) 1.05 (0.83-2.37) 
 
Gestation at enrolment     
     Second trimester 761 22.3 1.00 1.00 
     Third trimester 193 23.8 0.96(0.74-1.25) 1.07 (0.79-1.44) 
 
Prior use of antimalarial 
drugs 
    
     Yes 49 34.7 1.00 1.00 
     No 920 22.1 0.64 (0.43-0.95) 0.77 (0.48-1.23) 
 
*- Anemia (hemoglobin <11g/dL) present at enrolment or at delivery  
N- Total number of women with information in the specified category 
†-percentage of women with anemia at either at enrolment or at delivery 
PR- Prevalence ratio; CI- Confidence interval; SP-sulfadoxine-pyrimethamine ; IPT-intermittent preventive 
therapy 
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 Table 3.7. The effect of frequency of P. falciparum infection during pregnancy on low birth weight and maternal anemia 
 
  
 Primigravidae 
 
Multigravidae Malaria Exposure 
N (%) Crude PR (95% CI) Adjusted PR† (95% CI) Crude PR (95% CI_) Adjusted †PR (95% CI) 
 
Low birth weight      
    No malaria 55 (6.95) 1.00 1.00 1.00 1.00 
    1 episode 38 (12.7) 2.71 (1.04-7.05) 2.72 (1.06-7.00) 1.13 (0.46-2.74) 1.26 (0.51-3.11) 
    2  or more episodes† 15 (20.8) 3.19 (1.10-9.21) 3.16 (1.11-9.04) 2.89 (0.76-11.00) 3.00 (0.79 -11.41) 
Maternal anemia      
    No malaria 139 (21.0) 1.00 1.00 1.00 1.00 
    1 episode 56 (23.0) 1.10 (0.54-2.21) 1.07 (0.52-2.19) 1.03 (0.58-1.81) 1.09 (0.62-1.91) 
    2 episodes 25 (36.8) 1.43 (0.63-3.24) 1.57 (0.70-3.54) 1.56 (0.57-4.31) 1.53 (0.54-4.30) 
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PR- Prevalence ratio; CI- Confidence interval, N- number of children with low birth weight 
r of visits, and body mass index and net usage † -Adjusted for gestation at enrolment, numbe
 
 
 
 Table 3.8. The effect of timing of P. falciparum infection during pregnancy on low birth weight and maternal anemia 
  
Malaria Exposure N (%) Crude PR (95% CI) Adjusted* PR† (95% CI) 
 
Low Birth Weight 
   
    No malaria 55 (7.0) 1.00 1.00 
    Antenatal only 26 (11.5) 2.12 (1.17-3.87.) 2.24 (1.21-4.13) 
    Delivery only 14 (16.7) 2.06 (0.89-4.78) 2.13 (0.90-5.01) 
    
    Second Trimester‡ 24 (14.6) 2.90 (1.59-5.30) 2.97 (1.60-5.53) 
    Third Trimester‡‡ 15 (10.3) 1.29 (0.58-2.91) 1.42 (0.63-3.22) 
 
Maternal Anemia 
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    No malaria 139 (21.0) 1.00 1.00 
    Antenatal only 39 (22.2) 0.99 (0.60-1.63) 1.03 (0.63-1.68) 
    Delivery only 19 (24.7) 1.47 (0.83-2.59) 1.52 (0.83-2.78) 
    
    Second Trimester‡ 29 (22.8) 0.89 (0.40-1.62) 0.94 (0.51-1.71) 
    Third Trimester‡‡ 28 (21.9) 1.39 (0.87-2.22) 1.44 (0.90-2.29) 
* Adjusted for bed-net use, gestation at enrolment, body mass and number of visits 
‡- 13 to 28 weeks gestation age 
‡‡- 29 weeks to term
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Abstract 
Context: In areas of endemic transmission, malaria in pregnancy is associated with severe 
maternal anemia and low-birth weight deliveries. New anti-malarial treatment regimens are 
urgently needed in sub-Saharan Africa because of the increase in drug resistance. 
  
Objective: We investigated the efficacy and safety of anti-malarial treatment regimens in 
pregnant women at two rural health centers in Blantyre, Malawi. 
 
Design, Setting and Patients: We conducted a randomized open-label clinical trial, 
recruiting 141 pregnant women. They were randomly allocated to 3 treatment groups: 
sulfadoxine-pyrimethamine (SP; 3 tablets, 500mg sulfadoxine and 25mg pyrimethamine per 
tablet); SP plus azithromycin (1g/day x 2 days); or SP plus artesunate (200mg/day x 3 days). 
Women received two doses of the pre-assigned treatment, administered 4 weeks apart. 
Heteroduplex tracking assays were performed to distinguish recrudescence from new 
infections. The number of recrudescent episodes in the three treatment groups was analyzed 
using the conditional risk set Cox-regression model. 
 
Main Outcome Measures: Recrudescence rates and adverse outcomes. 
 
Results: All treatment regimens were well tolerated. Two women vomited soon after 
ingesting azithromycin. Recrudescent episodes of malaria were less frequent with SP-
azithromycin [Hazard Ratio 0.14 (95% confidence interval 0.02 to 0.78)] and SP-artesunate 
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[Hazard Ratio 0.13 (95% confidence interval 0.03 to 0.53)] compared with SP monotherapy. 
There were more abortions in the SP-azithromycin group, and more stillbirths in the SP-
artesunate groups, but they were probably unrelated to treatment. Because of the small 
sample size, the effect on birth outcomes, maternal malaria or maternal anemia could not be 
evaluated.  
 
Conclusion: Both SP-artesunate and SP-azithromycin appeared to be safe, well tolerated and 
efficacious for the treatment of malaria during pregnancy. A larger study is needed to 
determine its safety and efficacy in preventing poor birth outcomes.  
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Introduction 
More than 30 million women become pregnant in malaria-endemic areas in Africa 
each year1. Infection with Plasmodium falciparum during pregnancy can cause maternal 
anemia, abortions, stillbirths, preterm deliveries and low birth weight2, 3. In areas of high 
transmission, most of the infections in pregnant women are asymptomatic and consequently, 
malaria infection may go undiagnosed4. All pregnant women in these areas should be 
provided with intermittent preventive therapy (IPT) at antenatal visits to prevent infection5. 
Sulfadoxine-pyrimethamine (SP), first introduced in Malawi in 1993, has now been adopted 
by many countries in sub-Saharan Africa as the drug of choice for IPT. Studies have shown 
that IPT significantly reduces the prevalence of placental malaria and low birth weight 
(LBW)6-11. 
 
The increase in the resistance to SP in sub-Saharan Africa is recognized as a growing 
public health problem12. There are currently few chemotherapeutic options available for 
treatment and prevention of malaria during pregnancy. In addition, limited data exist on the 
safety of anti-malarial drugs as pregnant women have been frequently excluded from most 
malaria treatment trials for fear of toxicity to the fetus13. Research is urgently needed to 
identify alternative anti-malarial drugs that are safe, acceptable and efficacious in treating 
and preventing malaria infection in pregnant women.  
 
The use of combination anti-malarial drugs that target different pathways is being 
strongly advocated as a strategy for improving efficacy and delaying the emergence of drug-
resistant parasites14. The combination of conventional anti-malarial drugs with artemisinin 
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derivatives has been proposed as the next best option for the treatment of resistant P. 
falciparum. Artesunate, one of the artemisinin derivatives, has been used widely in South-
East Asia in non-pregnant individuals. There have been no reports of severe adverse effects 
in studies when it was given as treatment in the second and third trimesters of pregnancy15, 16. 
However, due to the small number of women in these studies, there is still need for more 
information on its safety in pregnant women. Azithromycin, a macrolide antibiotic, which 
has been found to have anti-malarial effect 17, 18, has been used in pregnant women to treat 
sexually transmitted infection (STIs), and other infections with a good safety profile19, 20. 
However, there have been no studies that have investigated its efficacy in treating malaria in 
pregnant women. The objective of this pilot study was to compare the efficacy and safety of 
SP combined with azithromycin or artesunate with SP monotherapy.  
 
Methods 
 
Study population 
 The study was conducted at Mpemba and Madziabango health-centers in Blantyre 
District, Malawi from September 2003 to September 2004. Blantyre district has a population 
of approximately 950,000 people21. Malaria transmission is perennial, but peaks during the 
rainy season (November–March).  P. falciparum causes over 90% of all malaria infections.  
The two health-centers have maternity beds for delivery of low risk pregnancies. Women 
with high risk pregnancies are referred to Queen Elizabeth Central Hospital (QECH), a 
tertiary hospital located about 10 km from the health centers for management. Women were 
eligible if they had peripheral parasitemia, were 15-49 years old, fetal gestation age 14-26 
 142
weeks, and were available for follow-up until delivery. Women were excluded if they had 
multiple gestation, a history of chronic diseases such as tuberculosis and diabetes, a mental 
disorder, known allergies to drugs containing sulfonamides, macrolides or pyrimethamine, 
pregnancy complications, or if they had taken anti-malarial drugs within 28 days before 
enrollment.   
 
Study procedures 
Written or witnessed verbal informed consent was obtained prior to enrollment. A 
standardized questionnaire was administered on demographic information, history of malaria 
illnesses, and past medical and obstetric history. The women received routine antenatal 
assessment and had the option to be tested for human immunodeficiency virus (HIV) 
infection, with pre- and post-test counseling. The HIV test was only done in women who 
accepted to have the test. A venous blood sample was obtained to measure hemoglobin 
concentration, prepare thick blood films, and HIV testing. Subjects were randomly assigned 
using computer generated random numbers to three treatment arms: (1) SP (3 tablets; 500mg 
sulfadoxine and 25mg pyrimethamine per tablet); (2) SP (3 tablets) plus azithromycin 
(1g/day for 2 days) and (3) SP (3 tablets) plus artesunate (200mg/day for 3 days). 
Administration of the drug was under direct observation. A full dose of the drug was re-
administered if the medication was vomited within 30 minutes of ingestion. Women stayed at 
the health-center for at least an hour after taking the drug. Women who lived far away spent 
2 nights at the health-center or were visited at home. The women were given 200mg of 
ferrous sulfate and 0.25mg of folic acid for daily administration, and insecticide treated bed-
nets (ITNs).  
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Follow-up 
Women received two doses of the assigned treatment, given on average 4 weeks 
apart. Thick films were examined for parasitemia on days 1,2,3,7 and 14 after each treatment, 
at subsequent antenatal visits, and at unscheduled visits.  Body temperature was recorded 
every 6 hours until it became normal (<37.5 0C). Symptoms present at baseline were 
considered to be attributable to malaria. Mild or moderate adverse events were monitored at 
the health-centers with outpatient management. All patients requiring hospitalization were 
monitored at the health-centers or referred to QECH. Women with parasitemia between days 
7 and 28 after taking the assigned treatment were given quinine (600mg, 3 times/day for 5 
days). The women were followed until delivery, and at each subsequent visit women 
received routine antenatal care, information was obtained on malarial illnesses, use of anti-
malarial drugs, and potential side effects of the study drugs. The women were asked not to 
self-administer anti-malarial drugs, but to return to the health-centers for evaluation any time 
they experienced symptoms of malaria.  
 
Delivery 
All HIV-positive women were given nevirapine (Roxane Laboratories, Columbus, 
Ohio, USA) at the onset of active labor according to the HIVNET 012 protocol22. Newborns 
delivered at the health-centers or QECH were weighed using a digital scale (to the nearest 
gram) and gestational age was estimated using the Ballard score within 24 hours of delivery 
23. A blood sample was obtained from a maternal peripheral vein, the placenta and umbilical 
cord for preparation of thick films and estimation of maternal hemoglobin concentration. Full 
thickness placental biopsies were collected to prepare histology slides. If a traditional birth 
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attendant was present during home deliveries, birth weight was measured using color-coded 
scales that indicated red for birth weight less than 2,500g and green for birth weight at least 
2,500g. Peripheral, placental and cord blood thick blood films were prepared and forwarded 
to the health-centers through community health workers.  
 
Outcome measures 
 
Treatment failure 
Recurrent episodes detected between days 7 and 14 were classified as recrudescence 
without genotyping, because they were assumed very unlikely to be new infections24. For 
recurrent episodes detected after day 14, we genotyped the msp-1 gene using a Heteroduplex 
Tracking Assay (HTA)25, 26 to distinguish between recrudescence and new infections. 
Genotyped recurrent episodes were classified as recrudescence if all the variants or a subset 
of the alleles (at least one identical uncommon band with prevalence <10% or at least 2 
common bands with a prevalence >10%) detected in a recurrent episode, were identical to 
those present in the initial infection.    
 
Maternal and birth outcomes 
Newborns were classified as having normal (≥ 2,500g) or low (< 2,500g) birth 
weight, regardless of gestational age. Prematurity was defined as delivery before 37 
estimated weeks of gestation. Abortion was defined as delivery of a non-viable fetus before 
28 weeks of gestation. Stillbirth was defined as delivery of a dead fetus after 28 weeks of 
gestation. Neonatal death was defined as death occurring during the first 27 completed day of 
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life. Women were defined as having anemia if they had hemoglobin concentration less than 
11g/dL.  
 
Laboratory procedures 
Malaria diagnosis was performed by microscopy of Giemsa stained thick blood films. 
Parasite density was estimated using an assumed leukocyte count of 6,000 leukocytes/μl of 
blood. A thick film was considered negative if no parasites were detected after examining 
100 microscopic fields each containing approximately 20 leukocytes. All thick films were 
read by two skilled microscopists. Discrepancies were solved by repeating the readings. An 
assay using real-time PCR and sequence-specific probes27 was used to detect point mutations 
in the genes, encoding dihydropteroate synthase (dhps) and dihydrofolate reductase (dhfr), 
which have been associated with SP resistance28. Fixed placental biopsies were wax 
embedded, and 4μm thick sections were cut onto slides. Histological slides were prepared by 
staining with Gurr’s modified Giemsa and/or Hematoxylin and Eosin. The slides were 
examined for presence of P. falciparum infected erythrocytes and hemozoin deposition in 
fibrin or monocytes29. Hemoglobin concentration was measured using a HemoCueÒ 
hemoglobinometer (HemoCue Incorporated, Angelholm, Sweden). HIV testing was 
performed using two enzyme immuno-assays, Determine HIV-1/2 Rapid Test (Abbott 
Laboratories, Illinois, USA) and Unigold Test (Trinity Biotech plc, Dublin, Ireland) 
according to the manufacturers’ instructions. Discordant results were resolved using a third 
assay, Hemastrip Rapid Test (ChemBio Diagnostic Systems).  
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Ethical approval
This study was approved by the College of Medicine Research Committee (University 
of Malawi) and the Institutional Review Boards of the University of North Carolina (Chapel 
Hill, NC).  
Statistical Analysis 
Data analysis was conducted using STATA version 8 (Stata Corporation, TX, USA). 
Baseline characteristics and birth outcomes across the treatment groups were compared using 
the Chi-square test for categorical variables, analysis of variance for normally distributed, 
and the Kruskal-Wallis tests for non-normally distributed continuous variables. The main 
efficacy end point was HTA-adjusted recrudescence rates determined by survival analysis. 
Follow-up time was calculated in days from initial infection to occurrence of an event 
(recrudescence), or censoring (delivery or loss to follow-up). Kaplan-Meier survival curves 
assessed the independent predictors of treatment outcome. Comparison of the survival curves 
was performed using the Log-rank test. A conditional risk-set Cox proportional hazards 
regression model compared the efficacy of the three treatment regimens30. The baseline 
hazard was stratified by the number of treatment doses received. A robust variance estimator 
was included in the model to account for the correlation in each individual31. Other 
covariates included in the analysis were baseline parasite density, gravidity, HIV status, and 
history of receiving quinine during the follow-up period. The baseline parasite density was 
log-transformed to obtain a normal distribution. Since the number of women with unknown 
HIV status was large, regression models were derived with and without this variable. Safety 
end points were the incidence of adverse events.  
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Results 
A total of 141 pregnant women with uncomplicated P. falciparum infection were 
recruited into the study, 47 women in each treatment group. Data on treatment allocation and 
follow-up losses are shown in Figure 1. Twenty-three women were lost to follow-up. 
Reasons included permanent movement from the study area (n=5), withdrawal from the 
study (n=16), and delivery outside the study area (n=2). The median follow-up period was 
102 days (range 2-178 days). All women received at least one treatment course of the 
assigned drug and 121 women received a second course. Of the samples obtained at 
enrollment, 138 (98%) were genotyped. Mutations were present in 132 (97%) of the samples 
at dhfr-59 and 118 (90%) of the samples at dhps-540.  The genotyping results imply a 
moderate to high level of SP resistance. 
  
Baseline characteristics 
There were no significant differences in most of the baseline demographic and 
clinical characteristics across the treatment groups (Table 1). Only 89 (63.1%) women 
accepted to have an HIV test result, and of these, 26 (29.2%) were HIV-positive. The 
proportions of HIV-infected women, although not significantly different, were higher in the 
SP [33.3%, (9/27)] and SP-azithromycin groups [34.5%, (10/29)] than in the SP-artesunate 
group [21.2%, (7/33)].    
 
Treatment efficacy 
Microscopic re-appearance of P. falciparum parasites after the first treatment was 
detected in 30 (24.8%) of the 121 evaluable women. HTA-genotyping indicated that 21 
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(70%) of these episodes were recrudescence. The overall median time to recrudescence was 
34 days (range 7-133 days). The highest recrudescence rates was 35% (14/40) in women 
receiving SP, compared with 9.5% (4/42) in women given SP-azithromycin, and 7.7% (3/39) 
for the SP-artesunate. Of the 9 new infections identified at the time of receiving the second 
treatment, 2 resulted in recrudescence (HTA-corrected), both in the SP-artesunate group, 
detected on days 34 and 104, respectively. Overall, recrudescent episodes were significantly 
less frequent in the SP-azithromycin [Hazard ratio (HR) 0.23, (95% confidence interval (CI) 
0.08-0.71)] and SP-artesunate treatment groups [HR 0.25 (95% CI 0.10-0.61)] compared 
with SP monotherapy (Figure 2).  
 
After adjusting for gravidity and baseline parasite density, recrudescent episodes of 
malaria were still less frequent in the SP-azithromycin [HR 0.19 (95% CI 0.06-0.63)] and the 
SP-artesunate groups [HR 0.25 (95% CI 0.10-0.65)] than with SP monotherapy.  There was 
no significant difference in efficacy between the SP-azithromycin and SP-artesunate groups. 
Recrudescent episodes remained less frequent in the SP-azithromycin [HR 0.14 (95% CI 0.02 
to 0.78)] and the SP-artesunate groups [HR 0.13 (95% CI 0.03 to 0.53)] after including HIV 
in the model. Sensitivity analysis confirmed that there were lower recrudescence rates in 
women who received the two combination therapies compared with those given SP 
monotherapy, after taking into account possible misclassification of recrudescence 32. 
 
Parasite clearance 
 SP-artesunate significantly accelerated the clearance of parasites compared with SP-
azithromycin or SP (Figure 3). By day 2, the parasite clearance rates were significantly 
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higher for women allocated to SP-artesunate [39/47, (83.0%)] than those given SP [12/47, 
(25.5%)] and SP-azithromycin [11/47, (23.4%)]; p< 0.001. By day 3, the parasite clearance 
rates for SP-artesunate were (46/47, 97.8%) compared with [33/47, (70.2%)] and [35/47, 
(74.5%)] in the SP and SP-azithromycin groups respectively. None of the women in the SP-
azithromycin and SP-artesunate groups had parasitemia on day 7. However, 4 (8.5%) women 
in the SP group still had parasitemia on day 7 and 2 (4.3%) were parasitemic on day 14.  
 
Maternal parasitological and hematological responses at delivery 
The prevalence of peripheral parasitemia at delivery was similar across the treatment 
groups (Table 2). There were more women with placental malaria diagnosed via microscopy 
for SP-azithromycin [10, (30.3%)] than SP [5, (16.1%)] and SP-artesunate [6, (17.1%)] 
groups, p< 0.05. However, histologically there was no significant difference in malaria 
prevalence across the treatment groups, SP [11, (47.8%)] vs. SP-azithromycin [9, (50.0%)] 
vs. SP-artesunate [13, (44.8%)), p=0.23. The maternal hemoglobin concentration was higher 
at delivery than at enrolment for all treatment groups [SP (12.6g/dL vs. 10.2g/dL); SP-
azithromycin (12.6g/dL vs. 10.0g/dL) and SP-artesunate (13.0g/dL vs. 10.5g/dL)], but there 
was no significant difference between the groups (p=0.48). 
 
Pregnancy outcomes 
Of the 118 deliveries with known outcomes, there were 109 live births, 4 spontaneous 
abortions and 5 still births (Table 2). All 4 abortions occurred in the SP-azithromycin group. 
Three of the abortions occurred 25-29 days after treatment. Two of these women had malaria 
at the time of abortion, of which one had HIV-coinfection; the other woman was HIV-
 150
positive. There was 1 stillbirth in the SP, none in the SP-azithromycin and 4 in the SP- 
artesunate group. Two stillbirths occurred after prolonged labor, 1 occurred after the mother 
had taken traditional medicine to induce labor, 1 had the cord around the neck at delivery, 
and in 1 stillbirth, the mother had a positive syphilis test at delivery. There were more 
neonatal deaths in the SP (n=4) compared with the SP-azithromycin (n=1) and the SP-
artesunate group (n=3). Four of the deaths occurred soon after delivery, secondary to 
premature delivery at 29-31weeks. Two neonatal deaths occurred a few hours after delivery 
due to complications of labor (obstructed labor). Thus, the abortions, still births and neonatal 
deaths all potentially had other proximal causes and were probably unrelated to treatment.  
 
 Kernicterus was detected in one infant, born at 36 weeks gestation, weighing 2,150g 
at delivery, whose mother was treated with SP. Table 3 contains further details related to the 
pregnancy outcomes. 
 
Birth weight 
One hundred and six (89.8%) of the 118 babies were weighed and gestational ages 
assessed within 24 hours of delivery. There was no difference in the gestation age between 
the groups, and no physical abnormalities were detected in any of the newborn babies. 
Although not significantly different, the mean birth weights of infants born to mothers in the 
SP (2,868.6g, SD 625.2g) and SP-artesunate (2,836.2g, SD 482.0g) was higher than the SP-
azithromycin group (2,784.7g, SD 536.6g) (Table 2).  
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Maternal adverse effects 
Artesunate and azithromycin were well tolerated. There were no serious or clinically 
significant treatment-associated adverse reactions reported. Early drug-induced vomiting 
occurred in 2 women given SP-azithromycin, who vomited the drug soon after ingestion. 
Mild adverse reactions frequently reported included general body pains 5.7% (8/141), 
headache 3.5% (5/141), vomiting 2.1% (3/141), anorexia 1.4% (2/141), nausea 1.4% (2/141), 
and diarrhea 1.4% (2/141). However, these symptoms were indistinguishable from malaria 
symptoms. There was no significant difference in the reporting of these symptoms across the 
treatment groups.  
 
Discussion 
Our results show that SP plus azithromycin or artesunate were more effective in 
treating malaria in pregnant women than SP monotherapy. In addition, the artesunate-
combination shortened the clearance time of parasites. Both regimens were well tolerated. No 
treatment-related severe adverse events were detected, but larger studies will be needed to 
rule out associations with abortions, still births and neonatal deaths. We did not find a 
significant difference in the birth weight, maternal hemoglobin concentration, peripheral and 
placental parasitemia across the treatment groups. This may have been due to the small 
sample size in this study.  
 
Recent studies have shown that the combination SP-artesunate is effective against 
uncomplicated P. falciparum infection in African children33, 34. However, very few studies 
have investigated the safety and efficacy of SP-artesunate in treating malaria during 
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pregnancy. A study conducted in Sudan found that SP-artesunate was efficacious in treating 
uncomplicated P. falciparum malaria in 32 pregnant women with no adverse effects35.  
Women who were exposed to SP-artesunate in Gambia during mass drug administration did 
not experience adverse effects and delivered babies with higher birth weight compared with 
women who did not receive treatment36. Other studies have also found that artesunate alone 
or in combination with mefloquine, atovaquone, proguanil or quinine was efficacious and 
safe in all trimesters of pregnancy15, 16, 37-39.  
 
However, SP-azithromycin may have several advantages. First, although the parasite 
clearance rate was slow compared with the SP-artesunate group, the rate of recrudescence 
was similar to SP-artesunate. Secondly, azithromycin has been used to treat STIs in pregnant 
women with a very good safety profile, and reduced the prevalence of low birth weight, and 
neonatal deaths19. Therefore, using SP-azithromycin to treat pregnant women with malaria 
may also protect mothers against other infectious causes of poor birth outcomes. Thirdly, 
azithromycin has a relatively long half-life compared with artesunate. The combination of 
artesunate with a long half-life partner drug could promote resistance to the partner 40.  
 
The two combination regimens were relatively well tolerated.  The minor side-effects 
reported by the women, were difficult to distinguish from symptoms of uncomplicated 
malaria. There were 4 abortions in the SP-azithromycin group which were probably not 
treatment-related. However, a larger study is needed in order to rule out the possibility of an 
association.  
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Malawi introduced SP as first-line treatment for uncomplicated P. falciparum 
infection and for IPT in 1993. However, the prevalence of clinical failure and mutations in 
parasite enzymes associated with resistance to SP have risen in recent years 41. We also found 
high prevalence levels of mutations (90-97%) associated with SP resistance, which may 
explain why SP monotherapy was inferior to SP combination therapies. Our results indicate 
that there will be need to change to other anti-malarial drugs in the near future. Choosing the 
optimal drug combination will depend on many factors such as transmission dynamics, cost, 
safety, dosing requirements and acceptability. There is also a need to consider interactions 
with anti-retroviral drugs in areas where the HIV prevalence is high, as is the case for 
Malawi 42. 
 
In conclusion, this pilot trial found that SP combined with azithromycin or artesunate 
was efficacious in treating and preventing malaria in pregnant women. These preliminary 
results are promising and should encourage further and larger treatment studies to confirm 
the efficacy and safety of the combination of SP with artesunate or azithromycin in pregnant 
women. This information will be very important for the formulation of anti-malarial drug 
policy. 
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 Table 4.1. The baseline characteristics of pregnant women enrolled into the clinical trial 
 
  Treatment Group   
Characteristic SP Only SP & Azithromycin SP & Artesunate P-value 
 
Age in years, mean (SD) 
 
21.6 (4.9) 
 
21.2 (4.8) 
 
20.9 (4.6) 
 
0.72 
Body weight in kg, mean (SD)  53.3 (5.9) 52.2 (6.1) 52.9 (5.9) 0.62 
Married (%) 44 (93.6) 38 (80.0) 43 (91.5) 0.18 
Education (%)     
    None 3 (6.4) 9 (19.2) 8 (17.0)  
    Primary 42 (89.4) 31 (65.9) 32 (68.1) 0.06 
    Secondary/Tertiary 2 (4.26) 7 (14.9) 7 (14.9)  
Gravidity, median [range] 
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1 (1-8) 1 (1-9) 1 (1-7)  
    Primigravidae (%) 27 (57.5) 25 (53.1) 28 (59.6) 0.91 
    Secundigravidae (%) 5 (10.60 7 (14.89) 4 (8.5)  
Gestation weeks at 1st consultation, mean (SD) 21.9 (3.6) 22.4 (3.1) 22..0 (3.2) 0.81 
Parasitemia/μl, geometric mean [range] 964.5 (180-22500) 1184.2 (150-22500) 686.6 (120-4260) 0.05 
Hemoglobin concentration (g/dL) 10.2 (1.8) 10.0 (1.4) 10.5(1.6) 0.27 
HIV Positive† (%) 9 (33.3) 10 (34.5) 7 (21.2) 0.45 
 
†Only 89 women accepted to have an HIV test; SP group (n=27), SP-azithromycin group (n=29), SP-artesunate group (n=33) 
 
 
 Table 4.2. Maternal and fetal outcomes according to treatment group 
 
  Treatment Group   
Outcome SP  SP & Azithromycin SP & Artesunate P-value 
 
Peripheral parasitemia at delivery (%)§ 10 (30.3) 10 (30.3) 8 (22.9) 0.15 
Placental parasitemia by microscopy (%)¶ 5 (16.1) 10 (30.3) 6 (17.1) 0.04 
Placental parasitemia by histology # 11 (47.8) 9 (50.0) 13 (44.8) 0.23 
Cord blood parasitemia  0 2 (4.3) 1 (2.1) 0.09 
Hemoglobin concentration††, g/dL (mean, SD) 12.6 (2.3) 12.6 (2.3) 13.0 (2.0) 0.59 
Maternal anemia (%) 8 (24.2) 8 (25.8) 5 (14.2) 0.48 
Spontaneous abortions (%) 0 4 (8.5) 0 0.02 
 
Still birth (%) 1 (2.1) 0 
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4 (8.5) 0.03 
Neonatal deaths (%) 4 (8.5) 1 (2.1) 3 (6.4) 0.34 
Gestational age at delivery†, weeks (median, 
IQR)  
38 (29-42) 36 (33-42) 37 (34-42) 0.21 
Birth weight , grams ‡, (mean, SD) 2868.6 (625.2) 2784.7 (536.6) 2836.2 (482.0) 0.87 
Low birth weight (%) 8 (22.2) 6 (20.0) 6(17.7) 0.45 
§ 101 women had peripheral parasitemia results; SP only (n=33), SP-azithromycin (n=33), SP-artesunate (n=35) 
¶99 women had placental parasitemia results; SP only (n=31), SP-azithromycin (n=33), SP-artesunate (n=35) 
#70 women had placental histology results; SP only (n=23), SP-azithromycin (n=18), SP-artesunate (n=29) 
††99 women had hemoglobin results; SP only (n=33), SP-azithromycin (n=31), SP-artesunate (n=35) 
† Estimated using the Ballard score  
Includes only live born singl‡ etons with birth weight 
 
 Table 4.3. Details of women who had adverse pregnancy outcomes 
 
 
Patient 
No 
Treatment 
Group 
Outcome Details related to death Days after 
last dose 
 
1 SP Stillbirth Prolonged labor 92 days 
2 SP NND after 5 days  Birth weight 2150g, had Kernicterus diagnosed by clinical symptoms 78 days 
3 SP NND after 9 days NA 142 days 
4 SP NND Preterm delivery at 29 weeks 33 days 
5 SP NND Preterm delivery at 29 weeks, birth weight 930g, MPs+ 30 days 
6 SP-Artesunate NND Preterm delivery at 28 weeks 29 days 
7 SP-Artesunate Stillbirth Full term delivery, weight 2.7kg, cord around the neck, MPs+  11 days 
8 SP-Artesunate NND Preterm delivery at 28 weeks, birth weight 1.3 kg  31 days 
9 SP-Artesunate Stillbirth  Full term, took traditional medicines to enhance labor, MPs+  99 days 
10 SP-Artesunate Stillbirth  Preterm delivery at 31 weeks, birth weight 2 kg, VDRL 1:64 positive and 
TPHA positive 
29 days 
11 SP-Artesunate Stillbirth  Prolonged labor, birth weight 2600g  127 days 
12 SP-Artesunate NND  Obstructed labor, birth weight 2600g  79 days 
13 SP-
Azithromycin 
NND  
163 Obstructed labor, birth weight 2800g, MPS+  54 days 
14 SP-
Azithromycin  
Abortion at 26 
weeks    
NA 4 days 
15 SP-
Azithromycin 
Abortion at 25 
weeks 
MPs+ 25 days 
16 SP-
Azithromycin 
Abortion at 27 
weeks 
HIV Positive, MPs+ 28 days 
17 SP-
Azithromycin 
Abortion at 27 
weeks 
HIV positive 29 days 
 
SP- sulfadoxine-pyrimethamine; NND- neonatal death; MPs-malaria parasites detected in the maternal peripheral or placental blood; NA-no 
information available related to the abortion or neonatal death; VDRL-Venereal Disease Research Laboratory test; TPHA- Treponema 
pallidum hemagglutination assay; HIV-human immunodeficiency virus
 
 141 women enrolled 
 
 
 
 
 
 
SP 
(47 women) 
SP- Azithromycin 
(47 women) 
SP-Artesunate 
(47 women) 
 
 
 
 
 
 
 
6 withdrew 
1 moved out 
of the area 
47 women received the 
first dose of study drug 
3 withdrew 
2 moved out 
of the area 
47 women received the 
first dose of study drug  
6 withdrew 
2 moved out 
of the area 
47 women received the 
first dose of study drug   
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2 delivered 
outside 
study area 
40 women received the 
second dose of study drug 
42 women received the 
second dose of study drug 
39 women received the 
second dose of study drug   
 
1 withdrew
 
 
 
 
 
 
38 finished follow-up 42 finished follow-up 38 finished follow-up   
 
Figure 4.1. Flow diagram of the study participants
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Figure 4.2. The rate of recrudescence according to treatment group 
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Figure 4.3. Parasite clearance time after treatment 
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 CHAPTER 5 
 
DISCUSSION 
 
 5.1. Specific AIM I  
We found that the risk of low birth weight and maternal anemia increased with the 
number of episodes of malaria experienced during pregnancy. Furthermore, the time of 
infection also had an effect on the risk of low birth weight and maternal anemia. The 
prevalence of low birth weight was higher when parasitemia was detected in the antenatal 
period, especially in the second trimester of pregnancy. In contrast, the prevalence of 
maternal anemia was higher in women who had infection late in pregnancy detected in 
the third trimester of pregnancy or at delivery compared with women who had 
parasitemia in the antenatal period or in the second trimester.  
 
 
These results present to date, a study of a large sample of women of all parities 
followed longitudinally during pregnancy to estimate the effect of timing and frequency 
of infection during pregnancy on low birth weight and maternal anemia. Most previous 
studies have examined the association between malaria and its adverse effects by 
measuring parasitemia at one time point during pregnancy, or examining placental 
histology at delivery 1-8 . However, there is a strong potential for misclassification when 
information on malaria infection is collected at one point in time during the entire 
pregnancy period because studies have shown that peripheral parasitemia is not a very 
sensitive indicator of the presence of P. falciparum infection during pregnancy 9,10. 
Although placental histology is the most sensitive indicator of infection with malaria 
during pregnancy 10, it has some limitations. The placenta can only be examined after 
delivery and some infections occurring early in pregnancy may completely resolve by the 
time of delivery, leaving no residual pathology 9,11,12. Therefore to increase the sensitivity 
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 of detecting parasitemia, and to reduce the probability of misclassification, we obtained 
blood samples from the pregnant women during pregnancy, and placental parasitemia at 
delivery. We did not examine placental biopsies and therefore could still have missed 
some of the women who had malaria during pregnancy.    
 
 Our study population was community based. We recruited women who were 
presenting at the two health centers for antenatal care. Surveys have shown that more 
than 90% of pregnant women in Malawi visit antenatal clinics at least once during 
pregnancy 13. Therefore the study sample was more likely representative of pregnant 
women living in rural areas in Malawi. Traditional birth attendants and community health 
workers were recruited to collect data for home deliveries to minimize loss to follow-up.  
Despite these measures, loss to follow-up was a concern in this investigation and 
occurred in part because of the highly mobile nature of the study population.  
 
We only recruited a very small sample of women in the first trimester of 
pregnancy. Previous studies have shown that women in Malawi tend to seek health care 
in the middle to- late second trimester 14,15. Therefore we were unable to investigate the 
impact of malaria infection during the first trimester of pregnancy. We also did not obtain 
information on HIV-serostatus which is associated with increased risk for malaria 
infection and its complications during pregnancy and therefore our estimates could be 
biased by lack of this information.     
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  Our findings have policy implications in preventing malaria during 
pregnancy. Currently, it is recommended that pregnant women in malaria endemic areas 
should receive at least two doses of sulfadoxine-pyrimethamine as intermittent preventive 
therapy (IPT) during pregnancy, one dose soon after quickening and the other dose in the 
third trimester of pregnancy 16. We found that the number of episodes of malaria 
experienced during pregnancy increased the risk of low birth weight and maternal 
anemia. This is especially important in HIV-infected women who are at risk for multiple 
infections during pregnancy17. In most malaria endemic areas women do not receive the 
recommended two doses of SP during pregnancy as IPT. A recent study conducted in 
Malawi found low compliance to IPT among pregnant women, especially multigravidae, 
despite widespread awareness on its benefits and recommended improved delivery 
mechanisms of IPT 18. Furthermore, most women in Malawi tend to present for antenatal 
care late in pregnancy 14,15. It is therefore important to ensure that women receive the 
required doses of IPT during pregnancy to reduce the number of infections. Pregnant 
women should be given SP even when they present for antenatal care late in pregnancy as 
this could still reduce the risk of low birth weight, because we found that infection late in 
pregnancy increased the risk of low birth weight more than early in pregnancy.  
Improved antenatal care services would be one way of improving compliance and 
coverage. In order to maximize the benefits of preventive measures such as use of 
insecticide-treated bed nets and intermittent preventive therapy, it is also important that 
women attend ANC at an earlier stage of pregnancy than is currently the case. However, 
this demands allocation of more resources to the health services in terms of manpower, 
training, stable drug supply and quantitative as well as qualitative improvements of health 
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 facilities. Health systems and services research is needed to improve effectiveness and 
efficiency of existing services and for a better prioritization of resource allocations so that 
more women will be motivated to use them. Since the majority of pregnant women do not 
have access to malaria preventive measures and other services delivered through health 
units, ways of administering anti-malarial drugs to this high risk group at community 
level, through accessible, acceptable and safe means need to be explored. Although the 
risk of malaria and its adverse effects was higher in primigravidae, multigravidae still 
represented a big proportion of women who had malaria who were also at risk for low 
birth weight and maternal anemia. Therefore multigravidae should also be targeted in 
prevention policies that are established to prevent malaria in pregnant women.  
We have identified the impact of timing and frequency of infection during 
pregnancy on low birth weight and maternal anemia. Few prospective studies have 
studies the evolution of infection during pregnancy and it effect on low birth weight and 
maternal anemia, recruiting women of all parities. A prospective study building on the 
research in this dissertation could offer more contribution to the knowledge of the 
pathophysiology of malaria during pregnancy. Future research studies could improve on 
the identification of malaria during pregnancy by including the examination of placental 
histology in addition to examining parasitemia at different points during pregnancy. 
Furthermore, recruiting women in the first trimester of pregnancy would be important to 
understand the impact of malaria at this point when embryogenesis takes place. Follow-
up of women during pregnancy while monitoring the growth of the fetus using more 
sensitive methods such as ultrasound sonography would provide more information on 
how malaria causes low birth weight during pregnancy.    
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 5.2. Specific AIM II 
 
For our second aim, we investigated the safety and efficacy of sulfadoxine-
pyrimethamine (SP) combined with azithromycin or artesunate compared with SP 
monotherapy in treating uncomplicated Plasmodium falciparum infection in pregnant 
women. We found high recrudescence rates when we used SP monotherapy compared 
with SP combined with azithromycin or artesunate to treat malaria in pregnant women.  
We also found high prevalence rates of mutations (90-97%) that are associated with SP 
resistance in our study population. Therefore, there will be need to change from SP 
monotherapy to a more efficacious regimen in the near future. Apart from two women 
who had drug induced vomiting n the SP-azithromycin treatment group, none of the other 
women reported severe adverse events that were directly related to treatment. 
Additionally, SP-artesunate significantly shortened the parasite clearance.  
 
This was the first study to investigate the use of SP-azithromycin and SP-
artesunate for treatment and prevention of malaria in pregnant women. The two 
combination regimens were relatively well tolerated.  The minor side-effects reported by 
the women, were indistinguishable from symptoms of uncomplicated malaria. There were 
more abortions in the SP-azithromycin group which were probably not treatment-related. 
However, a larger study is needed in order to determine if the abortions were treatment 
related. There were more stillbirths in the SP-artesunate group compared with the other 
two groups. However, they were directly related to obstetric complications. Most of the 
neonatal deaths were secondary to premature delivery. The prevalence of neonatal deaths 
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 and stillbirths found in our study are similar to reports from other studies in Blantyre 
(personal communication Dr Metaferia). 
 
The median follow-up period was 80 days. Therefore we were able to detect most 
of the recrudescent infections. We performed molecular genotyping using a Heteroduplex 
tracking assay 19,20, to differentiate between recrudescent and new infections because of 
the long follow-up time. However, it is possible that a patient might have had a new 
parasite infection that had the same multilocus genotype as the pretreatment infection. 
We conducted a sensitivity analysis to assess the impact of such misclassification on our 
results and found that the combination therapies were still significantly more efficacious 
compared with SP monotherapy.  
 
One of the limitations of our study was that information on the use of anti-
malarials outside the study setting was self-reported and was not confirmed by measuring 
drug levels in urine or blood. This could have underestimated or overestimated our 
results, depending on the efficacy of the drugs obtained outside the study settings. In 
addition, the overall sample size was small and therefore we had low power to detect 
significant association of the some of the outcomes if present. 
 
There is a big overlap in the geographical distribution of malaria and HIV. In 
most malaria-endemic areas, the prevalence of HIV in women in the reproductive age is 
high 21. Studies have suggested that the immune response against malaria in women co-
infected with HIV is impaired 17. A number of studies from Malawi and Kenya have 
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 shown that P. falciparum parasitemia occurs more frequently in HIV-infected pregnant 
women 22. These women required more doses of SP to prevent malaria 23. The optimum 
approach to IPT in women who are HIV-positive is still not known. Most of the women 
in our study refused to have an HIV test. Therefore we were unable to conduct further 
analysis to assess the effect of HIV on efficacy on the combination therapies. More 
research is therefore needed to assess if the efficacy of the combination therapies would 
be affected by coinfection with HIV.  
 
Currently, there is a big drive to roll-out antiretroviral medication on a large scale 
in areas where HIV prevalence is high. However, there is limited information on the 
interaction between anti-malarial and antiretroviral drugs. One study found that HIV-1 
protease inhibitors, ritonavir and saquinavir decrease CD36-mediated adhesion of 
parasitized erythrocytes, and non-opsonic phagocytosis of parasitized erythrocytes by 
human macrophages, which may modify malaria sequestration in vivo 24. This might lead 
to decreased phagocytosis of parasitized erythrocytes, higher parasite densities and 
possibly more severe infection. As numerous trials are being conducted to identify new 
alternatives to SP for the treatment and prevention of malaria in pregnant women, there is 
also need for research on how these new drugs would interact with antiretroviral drugs as 
this could present a substantial problem in most malaria endemic areas.  
 
While there is urgency to offer more effective treatment whilst minimizing the 
risks of developing further drug resistance, there are still many operational constraints 
such as affordability, acceptability, and adherence by patients and access through public 
and private sectors. In order to obtain the benefits of combination therapy and protect the 
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 component drugs, complete adherence to the full recommended dosing regimen is 
necessary. Long-duration regimens, complex dosing schemes, high cost, poor 
understanding of how or why to adhere to recommended regimens, and adverse reactions 
to treatment contribute to non-adherence. A more comprehensive operational research, 
information gathering and consultation strategy needs conducted before recommended 
wide use of the combination therapies in pregnant women. 
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